WO2005037222A2 - Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci - Google Patents

Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci Download PDF

Info

Publication number
WO2005037222A2
WO2005037222A2 PCT/US2004/034206 US2004034206W WO2005037222A2 WO 2005037222 A2 WO2005037222 A2 WO 2005037222A2 US 2004034206 W US2004034206 W US 2004034206W WO 2005037222 A2 WO2005037222 A2 WO 2005037222A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
kda
bcg
tuberculosis
recombinant
Prior art date
Application number
PCT/US2004/034206
Other languages
English (en)
Other versions
WO2005037222A3 (fr
Inventor
Marcus A. Horwitz
Gunter Harth
Michael V. Tullius
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to US10/595,385 priority Critical patent/US7622107B2/en
Priority to EP04795381A priority patent/EP1684798A4/fr
Publication of WO2005037222A2 publication Critical patent/WO2005037222A2/fr
Publication of WO2005037222A3 publication Critical patent/WO2005037222A3/fr
Priority to US12/296,660 priority patent/US8163294B2/en
Priority to US12/296,666 priority patent/US8287879B2/en
Priority to US12/581,795 priority patent/US8124068B2/en
Priority to US12/986,598 priority patent/US8383132B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Definitions

  • the present invention generally relates to immunogenic compositions derived from recombinant attenuated intracellular pathogenic bacteria. More specifically, the present invention relates to immunogenic compositions comprising recombinant attenuated Mycobacteria that over express and secrete major extracellular proteins. Moreover, the immunogenic compositions of the present invention also comprise recombinant attenuated Mycobacteria including auxotrophic, prototrophic and metabolically impaired strains. The immunogenic compositions of the present invention are useful in inducing immune responses in hosts.
  • Intracellular bacteria have proven to be particularly intractable in the face of therapeutic or prophylactic measures.
  • Intracellular bacteria including the genus Mycobacterium, complete all or part of their lifecycle within the cells of the infected host organism rather than extracellularly.
  • intracellular bacteria are responsible for untold suffering and millions of deaths each year. Tuberculosis is the leading cause of death from a single disease agent worldwide, with 8 million new cases and 2 million deaths annually.
  • intracellular bacteria are responsible for millions of cases of leprosy.
  • debilitating diseases transmitted by intracellular agents include cutaneous and visceral leishmaniasis, American trypanosomiasis (Chagas disease), listeriosis, toxoplasmosis, histoplasmosis, trachoma, psittacosis, Q-fever, and legionellosis.
  • M. tuberculosis a major cause of death in developing countries.
  • human pulmonary tuberculosis primarily caused by M. tuberculosis is a major cause of death in developing countries.
  • Mycobacterium tuberculosis is capable of surviving inside macrophages and monocytes, and therefore may produce a chronic intracellular infection.
  • Mycobacterium tuberculosis is relatively successful in evading the normal defenses of the host organism by concealing itself within the cells primarily responsible for the detection of foreign elements and subsequent activation of the immune system.
  • tuberculosis resistance to one or more drugs was reported in 36 of the 50 United States. In New York City, one-third of all cases tested was resistant to one or more major drugs. Though non-resistant tuberculosis can be cured with a long course of antibiotics, the outlook regarding drug resistant strains is bleak. Patients infected with strains resistant to two or more major antibiotics have a fatality rate of around 50%. Accordingly, safe and effective immunogenic compositions against multi-drug resistant strains of M. tuberculosis are sorely needed.
  • M. tuberculosis When M. tuberculosis is not controlled by the infected subject it often results in the extensive degradation of lung tissue.
  • lesions are usually formed in the lung as the tubercle bacilli reproduce within alveolar or pulmonary macrophages. As the organisms multiply, they may spread through the lymphatic system to distal lymph nodes and through the blood stream to the lung apices, bone marrow, kidney and meninges surrounding the brain.
  • characteristic granulomatous lesions or tubercles are produced in proportion to the severity of the infection. These lesions consist of epithelioid cells bordered by monocytes, lymphocytes and fibroblasts. In most instances a lesion or tubercle eventually becomes necrotic and undergoes caseation (conversion of affected tissues into a soft cheesy substance).
  • M. tuberculosis is a significant pathogen
  • other species of the genus Mycobacterium also cause disease in animals including man and are clearly within the scope of the present invention.
  • M. bovis is closely related to M. tuberculosis and is responsible for tubercular infections in domestic animals such as cattle, ' pigs, sheep, horses, dogs and cats.
  • M. bovis may infect humans via the intestinal tract, typically from the ingestion of raw milk. The localized intestinal infection eventually spreads to the respiratory tract and is followed shortly by the classic symptoms of tuberculosis.
  • M. leprae that causes millions of cases of the ancient disease leprosy.
  • M. kansasii M. avium intracellulare
  • M. fortuitum M. marinum
  • M. chelonei M. scrofulaceum.
  • the pathogenic mycobacterial species frequently exhibit a high degree of homology in their respective DNA and corresponding protein sequences and some species, such as M. tuberculosis and M. bovis, are highly related.
  • the World Health Organization considers the BCG immunogenic compositions an essential factor in reducing tuberculosis worldwide, especially in developing countries.
  • the BCG immunogenic composition confers cell- mediated immunity against an attenuated mycobacterium that is immunologically related to M. tuberculosis.
  • the resulting immune response should inhibit primary tuberculosis.
  • primary tuberculosis is inhibited, latent infections cannot occur and disease reactivation is avoided.
  • BCG immunogenic compositions are provided as lyphophilized cultures that are re-hydrated with sterile diluent immediately before administration.
  • the BCG immunogenic composition is given at birth, in infancy, or in early childhood in countries that practice BCG vaccination, including developing and developed countries.
  • Adult visitors to endemic regions who may have been exposed to high doses of infectious mycobacteria may receive BCG as a prophylactic providing they are skin test non-reactive.
  • Adverse reactions to the immunogenic composition are rare and are generally limited to skin ulcerations and lymphadenitis near the injection site. However, in spite of these rare adverse reactions, the BCG immunogenic composition has an unparalleled history of safety with over three billion doses having been administered worldwide since 1930.
  • United States patent number (USPN) 5,504,005 (the '"005" patent") and USPN 5,854,055 (the "'055 patent”) both issued to B.R. Bloom et al., disclose theoretical rBCG vectors expressing a wide range of cell associated fusion proteins from numerous species of microorganisms.
  • the theoretical vectors described in these patents are either directed to cell associated fusion proteins, as opposed to extracellular non-fusion protein antigens, and/or the rBCG is hypothetically expressing fusion proteins from distantly related species.
  • the recombinant cell associated fusion proteins expressed in these models are encoded on UN tnat is integrated into the host genome and under the control of heat shock promoters. Consequently, the antigens expressed are fusion proteins and expression is limited to levels approximately equal to, or less than, the vector's native proteins.
  • United States patent number 5,830,475 also discloses theoretical mycobacterial immunogenic compositions used to express fusion proteins.
  • the DNA encoding these fusion proteins resides in extrachromosomal plasmids under the control of mycobacterial heat shock protein and stress protein promoters.
  • the immunogenic compositions disclosed are intended to elicit immune responses in non-human animals for the purpose of producing antibodies thereto and not shown to prevent intracellular pathogen diseases in mammals.
  • the '475 patent does not disclose recombinant immunogenic compositions that use protein specific promoters to express extracellular non-fusion proteins.
  • United States patent number 6,467,967 issued to the present inventor, claims immunogenic compositions comprising a recombinant BCG having an extrachromosomal nucleic acid sequence comprising a gene encoding a M. tuberculosis 30 kDa major extracellular protein, wherein said M. tuberculosis 30 kDa major extracellular protein is over-expressed and secreted.
  • the present inventors have filed continuation-in-part applications (United States patent application serial numbers 10/261 ,981 filed September 30, 2002, now abandoned and 10/439,611 filed May 15, 2003) claiming additional recombinant BCG that over- express other M. tuberculosis major extracellular proteins.
  • the present invention accomplishes the above-described and other objects by providing a new class of immunogenic compositions and immunotherapeutics and methods for the diagnosis, treatment, prevention, inhibition or palliation of intracellular pathogen diseases in mammals.
  • intracellular pathogen immunogenic compositions and immunotherapeutics have been prepared from the intracellular pathogen itself or a closely related species. These old immunogenic composition models were composed of the entire microorganism or subunits thereof.
  • the first, and currently only available immunogenic composition for Mycobacterium tuberculosis (Mtb) is an attenuated live immunogenic composition made from the closely related intracellular pathogen M. bovis.
  • Mtb Mycobacterium tuberculosis
  • Mtb Mycobacterium tuberculosis
  • the present inventors have discovered that specific extracellular products of intracellular pathogens that are secreted into growth media can be used to illicit potent immune responses in mammals either as individual subunits, or in subunit combinations.
  • the present invention discloses multiple related vaccine compositions and corresponding vaccine strategies predicated on the same inventive concept but modified to achieve different immunoprotective objectives.
  • the unifying inventive concept is the use of a transformed, or recombinant, BCG (rBCG) as the primary vaccine.
  • the rBCG expresses one or more antigenic polypeptides derived from an intracellular pathogen other than the un-transformed BCG itself.
  • An exemplary embodiment of this unifying inventive concept is a rBCG that expresses recombinant M. tuberculosis major extracellular proteins.
  • One immunoprotective strategy of the present invention is prime-boost vaccination.
  • Prime-boost involves administering a first immunogenic composition followed by a second, related, but different immunogenic composition (See for example Ramshaw I A, and Ramsay AJ. 2000.
  • the prime-boost strategy exciting prospects for improved vaccination.
  • the present invention describes a prime-boost vaccination strategy by which a recombinant BCG over expressing a M. tuberculosis major extracellular protein is administered first, followed at a later time by the administration of the purified M. tuberculosis major extracellular protein.
  • the administration of the vaccine in this way induces enhanced protection over that achieved by immunization with BCG alone, by immunization with a recombinant BCG over-expressing the M. tuberculosis 30 kDa major secretory protein (also known as Antigen 85B) (rBCG30) alone, or even by immunization with BCG first followed later by immunization with the purified M.
  • the first immunization uses rBCG30, a rBCG strain over expressing the M. tuberculosis 30 kDa major secretory protein, a.k.a. Antigen 85B or r30
  • the second immunization uses purified M. tuberculosis 30 kDa major secretory protein.
  • the purified M. tuberculosis 30 kDa major secretory protein may be extracted from whole cells, extracted from culture wherein M. tuberculosis has been previously cultivated, or produced using recombinant technologies.
  • the second immunization may be a truncated polypeptide having an immunodominant epitope of the M. tuberculosis 30 kDa major secretory protein.
  • a second related vaccine composition and immunoprotective strategy is useful in treating immunosuppressed individuals using a growth regulatable rBCG.
  • growth regulatable refers to an organism that only divides when provided with a specific nutrient. The specific nutrient is either co-administered with the immunogenic composition, provided to the immunogenic composition recipient subsequently or the rBCG must be "pre-loaded” with the nutrient.
  • the growth regulatable rBCG may be used alone, or as part of a prime-boost strategy.
  • the growth regulatable rBCG may be an auxotroph or possess an altered gene such that a required metabolic function is disabled (metabolically impaired).
  • an exemplary embodiment includes, but is not limited to, a metabolically impaired rBCG having a defective or deleted gene that normally encodes for a siderophore (microbial iron chelator).
  • the siderophore deficient rBCG can be "pre-loaded" with an essential mineral in an amount sufficient to permit a limited number of divisions. Thus, when the stored mineral is depleted the siderophore deficient rBCG ceases multiplying in the host.
  • the siderophore is either mycobactins or exochelins and the essential mineral is iron.
  • the growth regulatable rBCG auxotroph is deficient in pantothenic acid.
  • a third related immunogenic composition includes a rBCG encoding for a plurality of recombinant M. tuberculosis major extracellular proteins wherein the genes encoding the major extracellular proteins reside on a plurality of separate plasmids.
  • This embodiment may be used alone, or as part of a prime-boost strategy and the rBCG having a plurality of separate antigen encoding plasmids may be an auxotroph or metabolically impaired rBCG.
  • One such immunogenic composition comprises a rBCG having a first extrachromosomal nucleic acid sequence comprising a genetic construct encoding a first M.
  • tuberculosis major extracellular protein and a second extrachromosomal nucleic acid sequence encoding the same or a different major extracellular protein.
  • the first major extracellular protein is expressed at a higher level than the second major extracellular protein and, as both the first and the second major extracellular protein are over expressed and secreted, an immune response is induced in an animal.
  • the first major extracellular protein is selected from the group consisting of the 32 kDa, 30 kDa and 23.5 kDa M. tuberculosis major extracellular proteins and the second major extracellular protein selected from the group consisting of the 32 kDa, 30 kDa and 23.5 kDa M. tuberculosis major extracellular protein wherein the first and second major extracellular proteins are different.
  • the immunogenic compositions of the present invention are made using recombinant strains of the Bacille Calmette Guerin, or BCG.
  • BCG Bacille Calmette Guerin
  • the recombinant BCG expresses major extracellular proteins of pathogenic mycobacteria including, but not limited to, M. tuberculosis, M. leprae and M. bovis, to name but a few.
  • the major extracellular proteins expressed by the rBCG include, but are not limited to, the 12 kDa, 14 kDa, 16 kDa, 23 kDa, 23.5 kDa, 30 kDa, 32A kDa, 32B kDa, 45 kDa, 58 kDa, 71 kDa, 80 kDa, and 110 kDa of Mycobacterium sp. and respective analogs, homologs and subunits thereof including recombinant non-fusion proteins, fusion proteins and derivatives thereof.
  • the immunogenic compositions of the present invention may be administered using any approach that will result in the appropriate immune response including, but not limited to, intradermal, subcutaneous, intramuscular, intranasal, intraperitoneal, oral, or inhalation. Following a suitable post inoculation period, the vaccinated mammals were challenged with an infectious M. tuberculosis aerosol. Mammals receiving the immunogenic composition of the present invention were remarkably disease free as compared to mammals receiving BCG alone, the major extracellular protein alone, or any combinations thereof.
  • FIG. 1 depicts Coomassie blue stained gels labeled 1 a and 1 b illustrating the secretion of Mycobacterium tuberculosis recombinant 30 kDa protein by transformed strains of BCG from culture filtrates.
  • FIG. 2 graphically depicts the results from two experiments labeled 2a and 2b designed to compare skin test results of guinea pigs inoculated with the recombinant BCG immunogenic composition expressing the 30 kDa major extracellular protein of M. tuberculosis, with BCG alone, with the recombinant 30 kDa protein alone, or with a sham immunogenic composition.
  • FIG. 3 graphically depicts the weight change in guinea pigs labeled 3a and 3b following post immunization challenge with M. tuberculosis.
  • FIG. 4 graphically depicts Colony Forming Units (CFU) of infectious M. tuberculosis recovered from guinea pigs' lungs (FIG. 4a) and spleens (FIG. 4b) following post immunization challenge with M. tuberculosis.
  • CFU Colony Forming Units
  • FIG. 5 graphically depicts the skin test response of guinea pigs to sham immunogenic composition, BCG alone and BCG administered with recombinant 30 kDa of M. tuberculosis.
  • FIG. 6 graphically depicts antibody titers to purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30), 32A kDa major extracellular protein (r32A) and 23.5 kDa major extracellular protein (r23.5) in animals sham- immunized or immunized with BCG Tice, rBCG30 Tice I, rBCG30 Tice III, rBCG23.5, rBCG30 +23.5 with the genes oriented in the same direction, rBCG30 +23.5 with the genes oriented in the opposite direction, or rBCG32A.
  • FIG. 7 graphically depicts cutaneous delayed-type hypersensitivity (DTH) of guinea pigs sham-immunized, immunized with BCG or rBCG30 Tice I alone, or immunized with BCG or rBCG30 Tice I as the prime and immunized with purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30) as the boost (prime-boost).
  • DTH cutaneous delayed-type hypersensitivity
  • FIG. 8 graphically depicts serum antibody titers to r30 in guinea pigs sham- immunized, immunized with BCG or rBCG30 Tice I alone, or immunized with BCG or rBCG30 Tice I as the prime and immunized with purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30) as the boost (prime-boost).
  • FIG. 9 graphically depicts CFU of infectious M. tuberculosis recovered from guinea pigs' lungs and spleens following post immunization challenge with M. tuberculosis in animals that were sham-immunized, immunized with BCG or rBCG30 alone, or immunized with BCG or rBCG30 as a prime and immunized with purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30) as the boost (prime-boost).
  • FIG. 10 depicts Coomassie blue stained gels illustrating the two-plasmid system for the expression of M. tuberculosis 30kDa protein in M. bovis Tice.
  • FIG. 11 depicts Coomassie blue stained gels illustrating the secretion of pGB9.2-30 expressed M. tuberculosis 30 kDa protein in various Mycobacteria.
  • FIG. 12 depicts the pGB9.2-30 plasmid as used in accordance with the teaching of the present invention.
  • FIG. 13 graphically depicts cutaneous delayed-type hypersensitivity (DTH) of guinea pigs sham-immunized, immunized with BCG or rBCG30 alone, or immunized with BCG or rBCG30 and boosted with purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30) as the boost (prime-boost).
  • DTH cutaneous delayed-type hypersensitivity
  • FIG. 14 graphically depicts CFU of infectious M. tuberculosis recovered from guinea pigs' lungs and spleens following post immunization challenge with M. tuberculosis in animals that were sham-immunized, immunized with BCG or rBCG30 alone, or immunized with BCG or rBCG30 and boosted with purified recombinant M. tuberculosis 30 kDa major extracellular protein (r30) (prime-boost).
  • auxotroph refers to a microorganism having a specific nutritional requirement NOT required by the wild- type organism. In the absence of the required nutrient the auxotroph will not grow whereas the wild-type will thrive.
  • Gene refers to at least a portion of a genetic construct having a promoter and/or other regulatory sequences required for, or that modify the expression of, the genetic construct.
  • Genetic Construct A "genetic construct” as used herein shall mean a nucleic acid sequence encoding for at least one major extracellular protein from at least one intracellular pathogen. In one embodiment of the present invention the genetic construct is extrachromosomal DNA.
  • growth regulatable refers to an auxotrophic or metabolically impaired form of the present invention's immunogenic compositions. Growth is regulated by providing a nutrient essential for the auxotroph's growth at a concentration sufficient to induce growth.
  • host refers to the recipient of the present immunogenic compositions.
  • exemplary hosts are mammals including, but not limited to, primates, rodents, cows, horses, dogs, cats, sheep, goats, pigs and elephants.
  • the host is a human.
  • host is synonymous with "vaccinees.”
  • Immunogen shall mean any substrate that elicits an immune response in a host.
  • Immunogens of the present invention include, but are not limited to major extracellular proteins, and their recombinant forms, derived from intracellular pathogens, such as, but not limited members of the genus Mycobacterium.
  • Immunogenic composition comprises a recombinant vector, with or without an adjuvant, such as an intracellular pathogen, that expresses and/or secretes an immunogen in vivo wherein the immunogen elicits an immune response in the host.
  • the immunogenic compositions disclosed herein may be a prototrophic, auxotrophic or metabolically impaired transformant.
  • the immunogenic compositions of the present invention may or may not be immunoprotective or therapeutic. When the immunogenic compositions of the present invention prevent, ameliorate, palliate or eliminate disease from the host then the immunogenic composition may optionally be referred to as a vaccine.
  • the term immunogenic composition is not intended to be limited to vaccines.
  • Major extracellular protein As used herein, the term “major extracellular protein” is synonymous with “major secretory protein.” The present inventors have previously described and characterized the mycobacterial major extracellular proteins of the present invention. The descriptions and characterization of the present major extracellular proteins can be found, without limitation, in United States patent number 6,599,510, issued July 29, 2003 to the present inventors, the entire contents of which are hereby incorporated by reference.
  • Metabolically impaired shall mean a recombinant expression vector, specifically a rBCG, that has an altered or deleted gene that is essential for normal metabolism. In the present case, the metabolic alteration results in a rBCG that cannot divide in vivo unless the nutrient is provided to the rBCG (pre-loading) prior to the rBCG being administered in vivo.
  • nucleic Acid Sequence As used herein the term “nucleic acid sequence” shall mean any continuous sequence of nucleic acids.
  • Prototrophic refers to a rBCG that that does not require any substance in its nutrition additional to those required by the wild-type.
  • Transformant refers to a microorganism that has been transformed with at least one heterologous or homologous nucleic acid encoding for a polypeptide that is expressed and/or secreted.
  • the transformant is BCG.
  • the following Detailed Description will include five distinct sections for ease of understanding and to assure enablement of all embodiments of the present invention.
  • the first section provides an introduction to the major inventive concepts of the present invention and a brief background summarizing important technical themes.
  • the second section describes the immunogenic compositions in detail.
  • the immunogenic compositions described therein include rBCG strains that are prototrophic, auxotrophic and metabolically impaired. Each rBCG is transformed to express one or a plurality of immunogens derived from intracellular pathogens; the exemplary embodiment being Mycobacterial major extracellular proteins.
  • the rBCG may have one or a plurality of extrachromosomal plasmids having nucleic acid sequences that encode for one or a plurality of immunogens.
  • the third section details representative methods for preparing the various plasmids used to transform the rBCG of the present invention.
  • Section four presents novel vaccination strategies, specifically a prime boost strategy using the rBCG previously described.
  • section five provides detailed examples of safety and efficacy testing conducted by the present inventors using the immunogenic compositions and vaccine strategies disclosed in sections II through IV.
  • the present invention is directed to generally immunogenic compositions comprising attenuated, or avirulent, recombinant intracellular pathogens that express and/or secrete recombinant immunogenic antigens of the same, or another species.
  • the immunogenic compositions of the present invention can be prototrophic, auxotrophic or metabolically impaired.
  • the immunogenic compositions of the present invention may be used alone, or as part of a prime-boost vaccination strategy.
  • a vaccination strategy and combined immunogenic compositions are disclosed that comprise a recombinant BCG over expressing at least one M. tuberculosis major extracellular protein administered first followed at a later time by the administration of the same M.
  • tuberculosis major extracellular protein(s) in pure or partially purified form induces enhanced protection over that achieved by immunization with BCG alone, by immunization with rBCG alone, or even by immunization with BCG first followed later by immunization with the purified M. tuberculosis major extracellular protein.
  • the immunogenic compositions of the present invention may express one or a plurality of immunogens.
  • the immunogens may include, but are not limited to major extracellular proteins derived from intracellular pathogens such as, but not limited to Mycobacteria sp.
  • the immunogenic compositions, such as rBCG may have one, or a plurality of extrachromasomal plasmids encoding for one or more immunogens.
  • Each immunogenic composition of the present invention can express at least one immunogen of various molecular weights specific for a given intracellular pathogen.
  • the present inventors have previously identified M. tuberculosis immunogens that can include, but are not limited to, the major extracellular proteins 12 kDa, 14 kDa, 16 kDa, 23 kDa, 23.5 kDa, 30 kDa, 32A kDa, 32B kDa, 45 kDa, 58 kDa, 71 kDa, 80 kDa, 110 kDa and respective analogs, homologs, subunits and degenerative variants thereof including recombinant non- fusion proteins, fusion proteins and derivatives thereof.
  • fusion proteins are defined to include, but not limited to, the products of two or more coding sequences from different genes that have been cloned together and that, after translation, form a single polypeptide sequence.
  • Mycobacterial strains of the present invention BCG Tice and BCG Connaught. Wild-type M. bovis BCG Tice was purchased from Organon and wild- type M. bovis BCG Connaught was obtained from Connaught Laboratories, Toronto, Canada. M. smegmatis 1-2c wild-type was a gift from Peadar O'Gaora [Imperial College, London, UK (Herrmann JL, O'Gaora P, Gallagher A, Thole JER and Young DB., 1996. Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis.
  • M. tuberculosis Erdman wild-type was obtained from the American Type Culture Collection (ATCC#35801).
  • M. tuberculosis Erdman was used to generate its isogenic mutants M. tuberculosis Erdman g/t?A1 ::Tn5 aph(Km r ), designated [g/t?A1 ::Km r ], and M. tuberculosis Erdman [Hyg r ; unmapped insertion].
  • the strains were maintained in 7H9 medium pH 6.7 (Difco) at 37°C in a 5% CO 2 -95% air atmosphere as unshaken cultures. Cultures were sonicated once or twice weekly for 5 min in a sonicating water bath to reduce bacterial clumping.
  • Escherichia coli strains used The following bacterial strains were used (in alphabetical order): E. coli strains: DH5 (recA1 endA1 gyrA96 thi-1 hsdR17(rK ⁇ mr ) supE44 relA1 acZa ) was obtained from Invitrogen; S17( ⁇ pir + recA thi pro hsdKM* [pLC28Cam r Str s ]) and SM10 ( ⁇ pir + Cam s Str r ) were gifts from Olaf Schneewind [University of Chicago, Chicago, IL (Cheng LW, Anderson DM and Schneewind O. 1997.
  • Escherichia coli strains were maintained in LB broth or agar medium at 37°C and mycobacterial strains were maintained in 7H9 broth medium or 7H11 agar medium at 37°C in a 5% CO 2 - 95% air atmosphere.
  • Relevant antibiotics were used at the following concentrations: Ampicillin at 100 ⁇ g/mL for E. coli and at 20 ⁇ g/mL for mycobacteria; apramycin at 50 ⁇ g/mL for E. coli and 30 ⁇ g/mL for mycobacteria; chloramphenicol at 30 ⁇ g/mL for E. coli, hygromycin at 250 ⁇ g/mL for E.
  • E. coli and 50 ⁇ g/mL for mycobacteria kanamycin at 50 ⁇ g/mL for E. coli and 20 ⁇ g/mL for mycobacteria; pyrazinamide at 50 ⁇ g/mL for mycobacteria; streptomycin at 30 ⁇ g mL "1 for E. coli; and tetracycline at 12.5 ⁇ g/mL for E. coli.
  • Incubations of E. coli strains were for 24 h, of M. smegmatis strains for 3 - 5 days, and of M. bovis and M. tuberculosis strains for 2 weeks at 37°C in a 5% CO 2 - 95% air atmosphere.
  • BCG When BCG enters a latent phase in the immunized host, it may cease expressing the 30 kDa major secretory protein as well as other endogenous proteins, as occurs when M. tuberculosis enters stationary phase. If the recombinant BCG were able to continue to produce the protein during latency, this might result in an enhanced immune response. To achieve this objective, present inventors have placed the 30 kDa protein gene under the control of a promoter (PhspX) active during latency.
  • PhspX promoter
  • This promoter is from the alpha-crystallin protein gene which is known to be expressed during late logarithmic and stationary growth and under hypoxic conditions; such conditions may in part mimic latency in vivo (Yuan Y, Crane DD and Barry III CE. 1996. Stationary phase-associated protein expression in Mycobacteria tuberculosis: Function of the mycobacterial -crystallin homolog. J. Bact. 178:4484-92; Sherman DR, Voskuil M, Schappinger D, Liao R, Harrell Ml, and Schoolnik GK. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding a-crystallin. Proc. Natl. Acad. Sci.
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBV1 , consisting of the vector backbone, a fragment of approximately 750 bp located directly upstream of the atg codon of the hspX gene (Rv2031c) of M. tuberculosis Erdman and considered the promoter region of this gene, and the 975 base pairs (bp) coding region of the 30 kDa protein gene (fbpB, Rv1886c), into BCG Tice bacteria (Stock #3).
  • the strain stably maintained the recombinant plasmid, even in the absence of the selective antibiotic hygromycin for 3 weeks or approximately 20 generations.
  • the recombinant strain was assayed for its capacity to express and secrete the recombinant 30 kDa protein by gel electrophoresis and immunoblotting with 30 kDa protein specific antisera. Analysis of digitized scans showed the secretion of 9.7 ⁇ g of 30 kDa protein by 5 x 10 9 CFU, a value about 2- fold higher than for wild-type BCG Tice (5.1 ⁇ g per 5 x 10 9 CFU).
  • Stock vials (Stock #1) were established in 10% glycerol at a concentration of 7.7 x 10 7 particles/mL and stored at -80°C. 2.
  • tuberculosis 30 kDa or 23.5 kDa Major Secretory Proteins a. BCG Containing pGB9.2 Constructs Expressing M. tuberculosis 30 kDa or 23.5 kDa Major Secretory Proteins alone i. rBCG-pGB9.2-30 ii. rBCG-pGB9.2-23.5 b. BCG Containing Two Plasmid Constructs - One Expressing the M. tuberculosis 30 kDa Major Secretory Protein and One Expressing M. tuberculosis 23.5 kDa Major Secretory Protein i. rBCG30 I (pMTB30) + pGB9.2-23.5 ( ii.
  • the plasmid pGB9.2 is present in recombinant BCG strains of the present invention at low copy number, allowing low level expression of M. tuberculosis extracellular proteins. Particularly when multiple proteins are expressed, low level expression may be desirable for stable maintenance of the strain and, based upon unpublished findings from this laboratory, for inducement of protective immunity.
  • the plasmid pGB9.2 is compatible with the shuttle vectors pSMT3 and pNBV1 so it can be placed in combination with them in one BCG host.
  • This recombinant strain was generated by electroporating the recombinant plasmid pGB9.2 (Harm et al., 2004) consisting of the vector backbone and the M. tuberculosis 30 kDa protein gene (Rv1886c; fbpB) preceded by approximately 500 bp of upstream DNA sequence (promoter region) and inserted into the Pac ⁇ site of the plasmid's multi-cloning site, into BCG Tice bacteria (Stock #3). The strain stably maintained the recombinant plasmid, even in the absence of the selective antibiotic kanamycin for 4 months or approximately120 generations.
  • the recombinant strain was assayed for its capacity to express and secrete the recombinant 30 kDa protein by gel electrophoresis and immunoblotting with 30 kDa protein specific antisera. Analysis of digitized scans showed the secretion of 14 ⁇ g of 30 kDa protein by 5 x 10 9 CFU, a value about 3-fold higher than for wild-type BCG Tice (5.0 ⁇ g per 5 x 10 9 CFU).
  • Stock vials (Stock #1) were established in 10% glycerol at a concentration of 5.0 x 10 7 particles/mL and stored at -80°C.
  • This recombinant strain was generated by electroporating the recombinant plasmid pGB9.2 (Harth et al., 2004), consisting of the vector backbone and the M. tuberculosis 23.5 kDa protein gene (Rv1980; mpt64) preceded by approximately 625 bp of upstream DNA sequence (promoter region) and inserted into the Pac ⁇ site of the plasmid's multi-cloning site, into BCG Tice bacteria (Stock #3). The strain stably maintained the recombinant plasmid, even in the absence of the selective antibiotic kanamycin for 4 months or approximately120 generations.
  • the recombinant strain was assayed for its capacity to express and secrete the recombinant 23.5 kDa protein by gel electrophoresis and immunoblotting with 23.5 kDa protein specific antisera. Analysis of digitized scans showed the secretion of 2 ⁇ g of 23.5 kDa protein (wild-type BCG Tice does not contain a 23.5 kDa protein gene because the genomic deletion RD2, which occurred during the generation of BCG strains from wild-type M. bovis before 1931 , eliminated approximately 11.5 kilobase (kb) M. bovis DNA, encompassing the corresponding M. tuberculosis genes Rv1978 to Rv1988).
  • This recombinant strain was generated by electroporating the recombinant plasmid pGB9.2 (Harth et al., 2004), consisting of the vector backbone and the M. tuberculosis 23.5 kDa protein gene (Rv1980; mpt64) preceded by approximately 625 bp of upstream DNA sequence (promoter region) and inserted into the Pad site of the plasmid's multi-cloning site, into rBCG30 Tice I bacteria (Stock #3). The strain stably maintained both recombinant plasmids, even in the absence of the selective antibiotics hygromycin and kanamycin for 4 months or approximately120 generations.
  • the recombinant strain was assayed for its capacity to express and secrete the recombinant 30 and 23.5 kDa proteins by gel electrophoresis and immunoblotting with 30 and 23.5 kDa protein specific antisera.
  • Analysis of digitized scans showed the secretion of 28 ⁇ g of 30 kDa protein by 5 x 10 9 CFU, a value 5.6- fold higher than for wild-type BCG Tice (5.0 ⁇ g per 5 x 10 9 CFU), and 2 ⁇ g of 23.5 kDa protein (wild-type BCG Tice does not contain a 23.5 kDa protein gene because the genomic deletion RD2, which occurred during the generation of BCG strains from wild-type M.
  • This recombinant strain was generated by electroporating the recombinant plasmid pGB9.2 consisting of the vector backbone and the M. tuberculosis 23.5 kDa protein gene (Rv1980; mpt64) preceded by approximately 625 bp of upstream DNA sequence (promoter region) and inserted into the Pad site of the plasmid's multi- cloning site, into rBCG30 Tice III (Stock #1 ).
  • the strain stably maintained both recombinant plasmids, even in the absence of the selective antibiotics hygromycin and kanamycin for 4 months or approximately 120 generations.
  • the recombinant strain was assayed for its capacity to express and secrete the recombinant 30 and 23.5 kDa proteins by gel electrophoresis and immunoblotting with 30 and 23.5 kDa protein specific antisera. Analysis of digitized scans showed the secretion of 34 ⁇ g of 30 kDa protein by 5 x 10 9 CFU, a value 6.8-fold higher than for wild-type BCG Tice (5.0 ⁇ g per 5 x 10 9 CFU), and 2 ⁇ g of 23.5 kDa protein (wild-type BCG Tice does not contain a 23.5 kDa protein gene because the genomic deletion RD2, which occurred during the generation of BCG strains from wild-type M.
  • the 30/32 kDa protein complex (Antigen 85 complex) are major secreted proteins of M. tuberculosis.
  • the present inventors have generated strains secreting the M. tuberculosis 30 kDa protein (Horwitz MA, Harth G. Dillon BJ, and Malesa-Galic S. 2000.
  • Recombinant BCG vaccines expressing the Mycobacterium tuberculosis 30 kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA. 97:13853-8; Horwitz MA. and Harth G. 2003.
  • Another strain expresses all three of the M. tuberculosis 30/32 kDa complex proteins. By expanding the repertoire of M. tuberculosis major extracellular proteins presented to the host immune system in abundance, these latter strains are anticipated to induce a more potent immune response against M. tuberculosis. 3.a.
  • rBCG32B Tice I This recombinant strain was generated by electroporating the recombinant ) plasmid pNBVI , consisting of the vector backbone, a fragment of approximately 250 bp located directly upstream of the atg codon of the 32B kDa protein gene (fbpC; Rv0129c) of M. tuberculosis Erdman and considered the promoter region of this gene, and the 1 ,020 bp coding region of the 32B kDa protein gene, into BCG Tice bacteria. 3.b.
  • rBCG30-32A (pNBV1-[30-32A]) [0083]
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone, a Hind ⁇ -Pac ⁇ fragment of approximatelyl ,500 bp, containing the M. tuberculosis Erdman 30 kDa protein gene promoter and coding regions (fbpB, Rv1886c), and a Pac ⁇ -BamH ⁇ fragment of approximatelyl ,600 bp, containing the M. tuberculosis Erdman 32A kDa protein gene promoter and coding regions (fbpA, Rv3804c).
  • the two genes are present on the recombinant plasmid in divergent orientation with regard to their 5'->3' sense DNA strands to prevent readthrough from one gene into the adjacent gene.
  • rBCG30-32A-32B (pNBV1-[30-32A-32B]) [0084] This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone, a /-/V ⁇ c/Ill-Pacl fragment of approximatelyl ,500 bp, containing the M. tuberculosis Erdman 30 kDa protein gene promoter and coding regions (fbpB, Rv1886c), a Pac ⁇ -Nde ⁇ fragment of approximately 1 ,600 bp, containing the M.
  • tuberculosis Erdman 32A kDa protein gene promoter and coding regions fbpA, Rv3804c
  • a Nde ⁇ -BamH ⁇ fragment of approximately 1 ,300 bp containing the M. tuberculosis Erdman 32B kDa protein gene promoter and coding regions (fbpC, Rv0129c).
  • the three genes are present on the recombinant plasmid in divergent orientation with regard to their 5'-»3' sense DNA strands to prevent readthrough from one gene into an adjacent gene. 4.
  • BCG Containing Constructs Expressing the 30 kDa Major Secretory Protein in Combination with Immunostimulatory Cytokines a. Cytokines Linked to M.
  • tuberculosis 30 kDa Protein by Tether i. rBCG30-Gly 6 Ser-GM-CSF(pNBV1 -[30-G 6 S-mGM- CSF]) ii. rBCG30-Gly 6 Ser-IFN ⁇ (pNBV1-[30-G 6 S-mlFN ⁇ ]) iii. rBCG30-Gly 6 Ser-IL2 (pNBV1-[30-G 6 S-mlL2]) iv. rBCG30-Gly 6 Ser-IL12 (pNBV1-[30-G 6 S-mlL12p40- G 6 S-mlL12p35]) b.
  • cytokines Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Interferon gamma (IFN ⁇ ), Interleukin 2 (IL2), and Interleukin 12 (IL12).
  • GM-CSF Granulocyte-Macrophage Colony Stimulating Factor
  • IFN ⁇ Interferon gamma
  • IL2 Interleukin 2
  • IL12 Interleukin 12
  • Cytokines Linked to M. tuberculosis 30 kDa Protein by Tether (Gly 6 Ser) 4.
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a /-//ndlll-SamHI fragment of approximately 1 ,900 bp containing the M.
  • the fragment containing the DNA sequence of the mature GM-CSF was inserted into the recombinant plasmid as an amplification product using the recombinant ATCC construct #39754.
  • the fragment containing the DNA sequence of the mature IFN ⁇ was inserted into the recombinant plasmid as an amplification product using the recombinant ATCC construct #39046.
  • the fragment containing the DNA sequence of the mature IL2 was inserted into the recombinant plasmid as an amplification product using the recombinant construct 9402pAHanti-HER2 (obtained from S. Morrison, UCLA).
  • rBCG30-Gly 6 Ser-IL12 (pNBV1-[30-G 6 S-mlL12p40-G 6 S- mlL12p35])
  • Cytokines Directly Fused to M. tuberculosis 30 kDa Protein rBCG30-GM-CSF-F (pNBVI -[30-mGM-CSF]) rBCG30-IFN ⁇ -F (pNBV1-[30-mlFN ⁇ ]) rBCG30-IL2-F (pNBV1-[30-mlL2]) iv.
  • rBCG30-IL12-F (pNBV1-[30-mlL12p40-G 6 S-mlL12p35)
  • Strains 4. b. i, ii, iii, and iv parallel strains 4. a. i, ii, iii, and iv exactly with the exception that they do not contain the Gly 6 Ser linker between the 30 kDa protein gene coding region and the mGM-CSF, mIFN ⁇ , mlL2, and mlL12p40 coding regions. 5. BCG Containing Construct with Fusion of M. tuberculosis 30 kDa Major Secretory Protein and M. tuberculosis 23.5 kDa Major Secretory Protein a.
  • rBCG30-23.5-F (pNBV1-[30-23.5-F])
  • Recombinant BCG expressing both the 30 and 23.5 kDa major secretory proteins on a single plasmid see USPN 6,599,510 or, as above, on separate compatible plasmids have been generated. In those constructs, the proteins were expressed individually. In this vaccine strain, the recombinant BCG expresses the two proteins as a fusion protein.
  • rBCG30-23.5-F (pNBV1-[30-23.5-F])
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a Hind ⁇ -BamH ⁇ fragment of approximately 2,200 bp containing the M. tuberculosis Erdman 30 kDa protein gene promoter and coding regions without the gene's stop codon (fbpB, Rv1886c) and approximately 700 bp containing the coding region of the mature M.
  • tuberculosis 23.5 kDa protein (Rv1980; mpt64) including this gene's stop codon, into BCG Tice bacteria (Stock #3).
  • the strain stably maintained the recombinant plasmid for approximately 9 months (approximately 270 generations) even in the absence of the selective antibiotic hygromycin.
  • the recombinant strain was assayed for its capacity to express and secrete a recombinant 30-23.5 i. e. a 53 kDa fusion protein by gel electrophoresis and immunoblotting with 30 and 23.5 kDa protein specific antisera.
  • M. tuberculosis major extracellular proteins of M. tuberculosis are potent immunoprotective antigens (Horwitz et al., 2000; Horwitz and Harth, 2003 and Horwitz et al., 1995). These vaccine strains over express the M. tuberculosis and M. smegmatis glutamine synthetase (GS), a protein that present inventors have shown is a major extracellular protein and an essential virulence factor of M. tuberculosis (Harth G, Clemens DL and Horwitz MA. 1994. Glutamine synthetase of Mycobacterium tuberculosis: extracellular release and characterization of its enzymatic activity. Proc. Natl.
  • rBCG-GS(MTB) (pNBV1-MtbGS) [0095] The plasmid pNBV1-MtbGS (Tullius MV, Harth G and Horwitz MA. 2001. High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism. Infect Immun. 69:6348-63, hereby incorporated by reference in its entirety) was electroporated into BCG Tice and transformants were selected on 7H11 agar containing 50 ⁇ g/mL hygromycin.
  • Two individual hygromycin resistant clones were randomly selected and cultured in 7H9,10% OADC, 0.05% Tween-80 (7H9-OADC- TW) medium containing 50 ⁇ g/mL hygromycin. Both clones were determined to be expressing large amounts of recombinant M. tuberculosis GS. To ensure a pure culture, one of the cultures was plated at low density and a single colony was reisolated. Initial freezer stocks of the strain were prepared from the reisolated clone. The expression of recombinant M. tuberculosis GS was verified by polyacrylamide gel electrophoresis and immunoblotting with polyvalent, highly specific rabbit anti-GS immunoglobulin. rBCG-GS(MTB) was found to produce approximately 9 times more GS per mL of culture than BCG Tice strains lacking the pNBV1-MtbGS plasmid.
  • rBCG-GS(MS) (pNBV1-MsGS)
  • the plasmid pNBV1-MsGS (Tullius et al., 2001) was electroporated into BCG Tice and transformants were selected on 7H11 agar containing 50 ⁇ g/mL hygromycin.
  • Two individual hygromycin resistant clones were randomly selected and cultured in 7H9-OADC-TW medium containing 50 ⁇ g/mL hygromycin.
  • One of the two clones was determined to be expressing large amounts of recombinant M. smegmatis GS. To ensure a pure culture, this culture was plated at low density and a single colony was reisolated.
  • Initial freezer stocks of the strain were prepared from the reisolated clone.
  • M. tuberculosis are potent immunoprotective antigens. These vaccine strains over express the M. tuberculosis and M. smegmatis superoxide dismutase (SOD), a protein that present inventors have shown is a major extracellular protein (Harth G and Horwitz MA. 1999. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: Extracellular proteins as potential novel drug targets. J. Exp. Med. 189:1425-35, hereby incorporated by reference in its entirety).
  • SOD M. smegmatis superoxide dismutase
  • Recombinant BCG TICE (rBCG30 Tice I) expressing the M. tuberculosis 30 kDa major extracellular non-fusion protein was prepared as follows.
  • the plasmid pMTB30 a recombinant construct of the E. coli/mycobacteria shuttle plasmid pSMT3, was prepared as previously described by the present inventors in Harth et al. (Harth G, Lee B-Y and Horwitz MA. 1997. High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets. Infect Immun 65:2321-8), the entire contents of which are hereby incorporated by reference.
  • Recombinant BCG30 Tice II (pNBV1-Pg/nA-MTB30), which over expresses the M. tuberculosis 30 kDa extracellular non-fusion protein, was prepared as follows. Plasmid pNBV1-Pg/t ⁇ A1-MTB30 was constructed by amplifying the coding region of the M. tuberculosis 30 kDa gene (including an ⁇ /cfel restriction site at the start codon and a ind ⁇ restriction site immediately downstream of the stop codon) and cloning this PCR product downstream of the M.
  • tuberculosis glnA1 promoter in the Nde ⁇ Hind ⁇ sites of pNBV1-BFRB (Tullius et al., 2001).
  • the plasmid was electroporated into M. bovis BCG Tice and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin. Several individual hygromycin resistant clones were randomly selected and cultured in 7H9 medium containing 50 ⁇ g/mL hygromycin. The expression and export of recombinant M.
  • tuberculosis 30 kDa protein were verified by polyacrylamide gel electrophoresis and immunoblotting with polyvalent, highly specific rabbit anti-30 kDa protein immunoglobulins.
  • rBCG30 Tice II was found to produce 24 times more 30 kDa antigen per mL of culture than BCG Tice harboring just the vector (pNBVI).
  • Recombinant BCG23.5 Tice I (pNBV1-Pg/r»A-MTB23.5), which over expresses the M. tuberculosis 23.5 kDa extracellular non-fusion protein, was prepared as follows. Plasmid pNBV1-Pg/t?A1-MTB23.5 was constructed by amplifying the coding region of the M. tuberculosis 23.5 kDa gene (including an Nde ⁇ restriction site at the start codon and BamH ⁇ and Hind ⁇ restriction sites immediately downstream of the stop codon) and cloning this PCR product downstream of the M.
  • tuberculosis glnA1 promoter in the Nde ⁇ Hind ⁇ sites of pNBV1-BFRB (Tullius et al., 2001).
  • the plasmid was electroporated into M. bovis BCG Tice and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin. Several individual hygromycin resistant clones were randomly selected and cultured in 7H9 medium containing 50 ⁇ g/mL hygromycin. The expression and export of recombinant M.
  • tuberculosis 23.5 kDa protein were verified by polyacrylamide gel electrophoresis and immunoblotting with polyvalent, highly specific rabbit anti-23.5 kDa protein immunoglobulins.
  • Recombinant BCG30/23.5 Tice I (pNBV1-Pg/r»A-MTB30/23.5), which over expresses the M. tuberculosis 30 kDa and 23.5 kDa extracellular non-fusion protein, was prepared as follows. Plasmid pNBV1-Pg/nA1-MTB30/23.5 was constructed by cloning a 1 kb BamHl fragment from pNBV1-Pg/t?A1-MTB23.5 (which includes the M.
  • the genes encoding the two proteins are oriented in the same direction on the plasmid with the gene encoding the 23.5 kDa protein upstream of the gene encoding the 30 kDa protein.
  • the plasmid was electroporated into M. bovis BCG Tice and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin.
  • This strain also produced the 23.5 kDa protein at a high level that was slightly greater than the amount of recombinant 30 kDa protein. Because BCG does not have a gene encoding the 23.5 kDa protein, no comparison could be made with the parental strain as was done for the 30 kDa protein.
  • Recombinant BCG30 Tice III (pNBV1-MTB30) [0105] Recombinant BCG30 Tice III (pNBV1-MTB30), which over expresses the M. tuberculosis 30 kDa major extracellular protein, was prepared as follows. This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and an approximately 1.5 kb M. tuberculosis Erdman DNA flanked by C/al and BamH ⁇ restriction sites and containing the coding region of the 30 kDa major extracellular protein and the promoter region immediately upstream of the coding region, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 30 kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 30 kDa protein specific antisera (14.4-fold over the BCG Tice wild-type background level at the beginning of the analysis and 11.5-fold at the end of the analysis).
  • a stock (Stock #1 ) was established in 10% glycerol at a concentration of 2.5x10 8 particles/mL and stored at - 80°C. 13.
  • Recombinant BCG23.5 Tice ll pNBV1-MTB23.5)
  • Recombinant BCG23.5 Tice II (pNBV1-MTB23.5), which over expresses the M. tuberculosis 30 kDa major extracellular protein, was prepared as follows. This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a approximately 1.4 kb M. tuberculosis Erdman DNA flanked by Pst ⁇ and BamHl restriction sites and containing the coding region of the 23.5 kDa major extracellular protein and the promoter region immediately upstream of the coding region, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 23.5 kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 23.5 kDa protein specific antisera (16.2 mg/L at the beginning of the analysis and 15.1 mg/L at the end of the analysis. Because BCG does not have a gene encoding the 23.5 kDa protein, no comparison could be made with the parental strain as was done for the 30 kDa protein.
  • a stock (Stock #1 ) was established on 08-24-2001 in 10% glycerol at a concentration of 3x10 8 particles/mL and stored at -80°C.
  • Recombinant BCG30/23.5 Tice IIA (pNBV1-MTB30/23.5 ⁇ t) (as used hereinafter "tt” refers to a genetic construct encoding for multiple major extracellular proteins where in the nucleic acid sequences encoding for each protein [genes] are orientated in the same direction relative to the 5' end of the genetic construct) over expresses both the M. tuberculosis 30 kDa and 23.5 kDa major extracellular proteins. The genes encoding the two proteins are oriented in the same direction.
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and two pieces of M.
  • tuberculosis Erdman DNA of approximately 1.5 and approximately 1.4 kb, flanked by C/al and Ndel (30 kDa protein gene and promoter) and Ndel and Ndel-BamHl (23.5 kDa protein gene and promoter) restriction sites and containing the coding and promoter regions immediately upstream of each of the two coding regions of the 30 and 23.5 kDa major extracellular proteins, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 30 and 23.5 kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 30 and 23.5 kDa protein specific antisera (for the 30 kDa protein, expression was 23.3-fold over the BCG Tice wild- type background level at the beginning of the analysis and 16.5-fold over the BCG Tice wild-type background level at the end of the analysis; for the 23.5 kDa protein, expression was 18.7 mg/L at the beginning of the analysis and 12.2 mg/L at the end of the analysis).
  • Recombinant BCG30/23.5 Tice MB (pNBV1-MTB30/23.5t4)
  • Recombinant BCG30/23.5 Tice MB (pNBV1-MTB30/23.5 ) (as used hereinafter "T ⁇ " refers to a genetic construct encoding for multiple major extracellular proteins where in the nucleic acid sequences encoding for each protein [genes] are orientated in the opposite direction relative to the 5' end of the genetic construct) over expresses both the M. tuberculosis 30 kDa and 23.5 kDa major extracellular proteins. The genes encoding the two proteins are oriented in opposite directions on the plasmid.
  • This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and two pieces of M. tuberculosis Erdman DNA of approximately 1.5 and approximately 1.4 kb, flanked by Clal and Ndel (30 kDa protein gene and promoter) and Ndel and Ndel-BamHl (23.5 kDa protein gene and promoter) restriction sites and containing the coding and promoter regions immediately upstream of the coding regions of the 30 and 23.5 kDa major extracellular proteins, into BCG Tice bacteria (Stock #2).
  • Recombinant BCG32A Tice I (pNBV1-MTB32A), which over expresses the M. tuberculosis 32A kDa major extracellular protein (a.k.a. Antigen 85A), was prepared as follows. This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a approximately 1.5 kb piece of M. tuberculosis Erdman DNA flanked by C/al and BamHl restriction sites and containing the coding region of the 32A kDa major extracellular protein and the promoter region immediately upstream of the coding region, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 32A kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 32A kDa protein specific antisera (10.5-fold over the BCG Tice wild-type background level at the beginning of the analysis and 8.1-fold at the end of the analysis).
  • a stock (Stock #1) was established in 10% glycerol at a concentration of 3x10 8 particles/mL and stored at -80°C.
  • Recombinant BCG(MB)30 Tice (pNBV1-MB30), which over expresses the M. bovis 30 kDa major extracellular protein, was prepared as follows. This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a approximately 1.5 kb piece of M. bovis wild-type (ATCC#19210) DNA flanked by Clal and BamHl restriction sites and containing the coding region of the 30 kDa major extracellular protein and the promoter region immediately upstream of the coding region, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 30 kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 30 kDa protein specific antisera (9.7-fold over the BCG Tice wild-type background level at the beginning of the analysis and 7.8-fold at the end of the analysis).
  • a stock (Stock #2) was established in 10% glycerol at a concentration of 2.5x10 8 particles/mL and stored at -80°C.
  • Recombinant BCG(ML)30 Tice (p ' NB V1 -ML30) [0111] Recombinant BCG(ML)30 Tice (pNBV1-ML30), which expresses the M. leprae 30 kDa major extracellular protein, was prepared as follows. This recombinant strain was generated by electroporating the recombinant plasmid pNBVI , consisting of the vector backbone and a approximately 1.3 kb piece of M. leprae DNA flanked by Clal and BamHl restriction sites and containing the coding region of the 30 kDa major extracellular protein and the promoter region immediately upstream of the coding region, into BCG Tice bacteria (Stock #2).
  • the strain stably maintained the recombinant plasmid, and the level of recombinant 30 kDa protein expression remained almost constant over a 12 month period in the absence of antibiotics, as confirmed by immunoblotting with 30 kDa protein specific antisera (9.7-fold over the BCG Tice wild-type background level at the beginning of the analysis and 9.3-fold at the end of the analysis).
  • a stock (Stock #1) was established in 10% glycerol at a concentration of 3x10 8 particles/mL and stored at -80°C.
  • the attenuated intracellular pathogen is a growth regulatable auxotroph or metabolically impaired organism hereinafter referred to collectively as growth regulatable immunogenic compositions.
  • Exemplary embodiments of the present invention are based on attenuated or avirulent recombinant BCG.
  • the present invention is not limited to recombinant BCG.
  • a growth regulatable immunogenic composition is an auxotroph it remains essentially immunologically inert until a sufficient quantity of the appropriate nutrient is provided to the host. Once the essential nutrient is provided, the auxotrophic immunogenic composition begins expressing and secreting the immunogen. Later, if desired, withholding the essential nutrient can halt the auxotroph's growth and antigen expression in situ.
  • the immunogenic compositions of the present invention utilize an auxotrophic transformant expressing an immunogen, the essential nutrient required to initiate the auxotroph's growth within the host can be administered either immediately before, concurrent with or immediately after the immunogenic composition is administered.
  • the essential nutrient can be withheld from the host at any time following administration of the immunogenic composition to stop proliferation of the auxotrophic transformant.
  • the growth regulatable immunogenic composition is metabolically impaired such that the immunogenic composition is only able to multiply for a finite number of generations.
  • the growth regulatable immunogenic composition is a siderophore mutant that does not express the gene required for mycobactin or exochelin production. Consequently, the siderophore mutant cannot transport essential minerals such as iron into the cell.
  • the siderophore mutant is cultivated with an exogenous source of siderophore and iron the growth regulatable immunogenic composition becomes "pre-loaded" with the required mineral.
  • the siderophore mutant After it has been introduced into the vaccinee the siderophore mutant will multiply through a finite number of divisions until the stored iron is depleted at which time multiplication ceases. However, during multiplication the siderophore mutant will continue to express genes encoding for selected immunogens located on extrachromosomal plasmids.
  • the present inventors previously engineered auxotrophs that require a nutritional supplement to grow in the vaccinated host. Therefore, if the vaccine begins to disseminate and cause disease, the vaccinated person need only stop taking the nutritional supplement to stop the vaccine from multiplying.
  • Another approach to this problem is to engineer a vaccine capable of undergoing only a limited number of multiplications - a number sufficient to induce a strong immune response but not harm the host.
  • the vaccines described here are such constructs. These BCG vaccines have a defect in siderophore production and hence in iron acquisition.
  • the bacteria can be iron-loaded with a sufficient amount of iron so that they subsequently are able to multiply for several generations in the absence of a siderophore.
  • the bacteria have a sufficient amount of stored iron to multiply for several generations and induce an immune response.
  • the organism can not acquire iron from the host to replenish the iron utilized in multiplication (Gobin, J., Moore, C.H., Reeve, Jr., J.R., Wong, D.K., Gibson, B.W., and Horwitz M.A. 1995. Iron acquisition by Mycobacterium tuberculosis: Isolation and characterization of a family of iron-binding exochelins. Proc. Natl. Acad. Sci. (USA) 92:5189-93). Eventually, the iron stores of the bacteria are depleted, and the bacteria are no longer able to multiply. Thus the bacteria are unable to cause serious disease in the immunocompromised host.
  • the BCG Tice mbtB gene was disrupted via allelic exchange.
  • the allelic exchange substrate was generated using a PCR strategy in which a BCG Tice mbtB locus with a 3.9 kb deletion was created and a Km r cassette was inserted at the site of the deletion.
  • This mutated allele was cloned into the allelic exchange vector pEX2 (a derivative of pEX1 [Tullius et al., 2003] in which the gfpuv gene, encoding green fluorescent protein, is replaced by the E.
  • coli codBA operon encoding cytosine deaminase
  • pEX2 ⁇ mbtB::Km r The codBA operon incorporated into the pEX2 plasmid allows for the positive selection of clones that have lost the plasmid using 5-fluorocytosine (5-FC), that CodA converts to the highly toxic 5-fluorouracil.
  • pEX2 ⁇ mbtB::Km r was electroporated into BCG Tice and transformants were selected on 7H11 containing 50 ⁇ g/mL hygromycin and 50 ⁇ g/mL kanamycin at the permissive temperature (32°C). Pooled transformants were grown in 7H9- OADC-TW broth containing 50 ⁇ g/mL hygromycin and 50 ⁇ g/mL kanamycin at the permissive temperature for approximately 10 generations.
  • the culture was plated on 7H10 containing 10 or 50 ⁇ g/mL kanamycin and 2% (w/v) sucrose or 2% (w/v) sucrose plus 1-10 ⁇ M 5-FC at the restrictive temperature (39°C) to select for clones that had undergone a homologous recombination event. Twenty-nine out of the 76 clones analyzed were found to be hygromycin sensitive indicating that the plasmid had been eliminated. Of these 29, only one appeared to have the correct genotype, as determined by Southern blotting, for an mbtB mutant.
  • the culture was likely a mixture of the mbtB mutant and wild-type cells that had become spontaneously resistant to kanamycin (not uncommon in mycobacteria) as the culture seemed to revert to a wild-type genotype.
  • the present inventors hypothesized that the mbtB mutant is actually a mycobactin auxotroph that can grow for a limited amount of time in the absence of mycobactin, but eventually stops growing, thus allowing the wild-type cells in the population to dominate the culture. This was not expected as a previously characterized M.
  • tuberculosis H37Rv mbtB mutant was reported to grow in broth medium without mycobactin (De Voss, J.J., Rutter, K., B.G. Schroeder, Su, H., Zhu, Y., and Barry, III, C.E. 2000, The salicylate- derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. (USA) 97:1252-1257). Therefore, the present inventors cultured the strain in the presence of mycobactin J and performed three rounds of colony purification in order to isolate a pure, and stable, clone. This was successful, and initial freezer stocks of the strain were prepared from this reisolated clone. The correct genotype of the mutant was confirmed by Southern blot analysis.
  • the rBCG-mbtB strain is indeed a mycobactin auxotroph. Growth of the strain is normal in 7H9-OADC-TW when supplemented with more than 20 ng/mL mycobactin J and growth is reduced at 2 ng/mL. At less than 0.2 ng/mL mycobactin J there is no visible growth.
  • rBCG-mbtB is a mycobactin auxotroph, the strain can multiply for several or many generations after removal of mycobactin J. The number of generations of growth is dependent on the level of mycobactin J in the medium in which the strain was initially grown.
  • the strain when the strain is grown in 7H9-OADC-TW supplemented with a high concentration of mycobactin J (10 or 20 ⁇ g/mL) and the cells washed to remove extracellular mycobactin J, the strain is capable of approximately 8 or 9 generations of growth in medium lacking mycobactin J.
  • mycobactin J 10 or 20 ⁇ g/mL
  • mycobactin J there is essentially no growth upon subculture of washed cells into medium lacking mycobactin J.
  • the strain is grown in the presence of less than 0.5 ⁇ g/mL mycobactin J and subcultured into medium lacking mycobactin J, there is a drop in viability of approximately 3 logs in 2 weeks.
  • Complementation analysis was also performed by transforming rBCG-mbtB with a plasmid containing the BCG Tice mbtB gene (pNBV1-mbtB). This plasmid restored a wild-type growth phenotype to the mutant.
  • rBCG-mbtB-30 (pMTB30) [0122J
  • the plasmid pMTB30 (pSMT3-30) was electroporated into rBCG-mbtB and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin, 10 ⁇ g/mL kanamycin, and 2 ⁇ g/mL mycobactin J.
  • Four individual hygromycin and kanamycin resistant clones were randomly selected and cultured in 7H9 medium containing 50 ⁇ g/mL hygromycin and 2 ⁇ g/mL mycobactin J.
  • rBCG-mbtB-30 like its parent strain rBCG-mbtB, is a mycobactin auxotroph.
  • tuberculosis glnA1 locus with a Km r cassette inserted into a unique site located near the middle of the glnA1 coding region.
  • Km r cassette inserted into a unique site located near the middle of the glnA1 coding region.
  • pEX1- Mtb-glnA1 ::Km r was electroporated into BCG Tice and transformants were selected on 7H11 containing 50 ⁇ g/mL hygromycin. The plates were initially kept at the permissive temperature (32°C) for 6 days and then incubated at the restrictive temperature (39°C) for 46 days.
  • a single transformant was grown in 7H9-10% OADC-0.05% Tween-80 broth culture with 50 ⁇ g/mL kanamycin and 20 mM L- glutamine at the restrictive temperature for approximately 25 generations and then plated on 7H11 containing 2% (w/v) sucrose, 20 mM L-glutamine, and 50 ⁇ g/mL kanamycin to select for clones that had undergone a second homologous recombination event. Twelve of 35 randomly selected Km r clones were found to have the correct phenotype (i.e. Hyg s and glutamine auxotroph). To ensure a pure culture, present inventors plated one of the twelve clones at low density and a single colony was reisolated. Initial freezer stocks of the strain were prepared from the reisolated clone. The correct genotype of the mutant was confirmed by Southern blot analysis.
  • the BCG Tice glnA1 strain is a glutamine auxotroph. No growth was observed on 7H11 plates without the addition of L-glutamine. Furthermore, the glnA1 mutant displayed little or no intracellular growth in human macrophages when macrophages were cultured in tissue culture medium containing 0.2 mM L-glutamine (conditions under which the wild-type strain grows normally). However, intracellular growth similar to the wild-type strain was achieved by adding a large excess of L- glutamine (10 mM) to the tissue culture medium. Complementation analysis was performed by transforming BCG Tice glnA1 with plasmids containing the M.
  • tuberculosis glnA1 gene pNBV1-MtbGS
  • S. typhimurium glnA gene pNBV1- StGS
  • Both plasmids restored a wild-type growth phenotype to the mutant.
  • the L- glutamine requirement of this BCG glnA1 auxotroph is expected to be very similar to that of a M. tuberculosis glnA1 strain that the present inventors have previously characterized in greater detail (Tullius et al., 2003).
  • high levels of L-glutamine (10-20 mM) were required in solid medium for the mutant to grow normally. In liquid medium, the M.
  • tuberculosis glnA1 mutant grew at a normal growth rate at more than 1 mM L-glutamine. Although initially growth was normal at 1-2 mM L-glutamine, these cultures did not reach as high a density as cultures containing 5 mM and 20 mM L-glutamine, and they exhibited a sharp drop in viability shortly after log-phase. The M. tuberculosis glnA1 strain lost viability rapidly when diluted into medium lacking L-glutamine. No growth of the M. tuberculosis glnA1 mutant occurred in human macrophages when the macrophages were cultured in the presence of 0.2 mM L-glutamine, a condition under which the wild-type strain grows normally.
  • M. tuberculosis glnA1 mutant Growth of the M. tuberculosis glnA1 mutant in human macrophages was poor when macrophages were cultured in standard tissue culture medium containing 2 mM L-glutamine. However, intracellular growth similar to the wild-type strain was achieved when macrophages were cultured in a large excess of L-glutamine (10 mM). The M. tuberculosis glnA1 mutant is highly attenuated in the guinea pig model of pulmonary tuberculosis.
  • B.3.b. BCG Tice trpD [0125] The BCG Tice trpD gene was disrupted via allelic exchange.
  • the allelic exchange substrate was generated using a PCR strategy in which a BCG Tice trpD locus with a 588 bp deletion was created and a Km r cassette was inserted at the site of the deletion.
  • This mutated allele was cloned into the allelic exchange vector pEX2 (a derivative of pEX1 in which the gfpuv gene, encoding green fluorescent protein, is replaced by the E. coli codBA operon, encoding cytosine deaminase) to generate pEX2 ⁇ trpD::Km r (Tullius et al., 2003).
  • the BCG Tice trpD strain is a tryptophan auxotroph. No growth was observed on 7H11 plates without the addition of L-tryptophan. In broth culture, the BCG Tice trpD strain grew at a rate similar to the wild-type strain in the presence of more than 10 ⁇ g/mL L-tryptophan. Growth was nearly twice as slow at 3 ⁇ g/mL L- tryptophan and the strain lost viability when diluted into medium lacking L- tryptophan.
  • the trpD mutant displayed little or no intracellular growth in human macrophages when macrophages were cultured in standard tissue culture medium which contains 5 ⁇ g/mL L-tryptophan (conditions under which the wild-type strain grows normally). However, intracellular growth similar to the wild-type strain was achieved by adding an additional 100 ⁇ g/mL L-tryptophan to the tissue culture medium. Complementation analysis was performed by transforming BCG Tice trpD with a plasmid containing the BCG Tice trpD gene (pNBV1-trpD). This plasmid restored a wild-type growth phenotype to the mutant.
  • B.3c. BCG Tice glnA1 pSMT3-MTB30 [0128] The plasmid pMTB30 (pSMT3-30) was electroporated into BCG Tice glnA1 and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin, 50 ⁇ g/mL kanamycin, and 20 mM L-glutamine. Two individual hygromycin and kanamycin resistant clones were randomly selected and cultured in 7H9 medium containing 50 ⁇ g/mL hygromycin, 50 ⁇ g/mL kanamycin, and 20 mM L-glutamine. The expression and export of recombinant M.
  • BCG Tice glnA1 pMTB30 was found to produce approximately 10-20 times more 30 kDa antigen per mL of culture than BCG Tice glnA1.
  • BCG Tice glnA1 pMTB30 like its parent strain BCG Tice glnA1 , is a glutamine auxotroph.
  • B.3.d. BCG Tice trpD pSMT3-MTB30 [0129] the plasmid pMTB30 (pSMT3-30) was electroporated into BCG Tice trpD and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin, 50 ⁇ g/mL kanamycin, and 50 ⁇ g/mL L-tryptophan.
  • B.4. Attenuated BCG (Prototroph) a.
  • BCG Tice narG [0130] The BCG Tice narG gene (encoding nitrate reductase alpha subunit) was disrupted via allelic exchange.
  • the allelic exchange substrate was generated using a polymerase chain reaction (PCR) strategy in which a BCG Tice narG locus with a 2952 bp deletion was created and a Km r cassette was inserted at the site of the deletion.
  • This mutated allele was cloned into the allelic exchange vector pEX2 (a derivative of pEX1 in which the gfpuv gene is replaced by the E. coli codBA operon) to generate pEX2 ⁇ narG::Km r (Tullius et al., 2003).
  • pEX2 ⁇ narG::Km r was electroporated into BCG Tice and transformants were selected on 7H11 agar containing 50 ⁇ g/mL hygromycin and 50 ⁇ g ⁇ g/mL kanamycin at the permissive temperature (32°C).
  • narGHJI Anaerobic nitrate reductase activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol. 35:1017-25). Hence, it is anticipated that the narG mutant strain will similarly be attenuated in SCID mice and, in addition, be attenuated in immunocompromised persons.
  • B.4.b. BCG Tice narG pSMT3-MTB30 [0132] The plasmid pMTB30 (pSMT3-30) was electroporated into BCG Tice narG and transformants were selected on 7H11 agar with 50 ⁇ g/mL hygromycin and 10 ⁇ g/mL kanamycin. Five individual hygromycin and kanamycin resistant clones were randomly selected and cultured in 7H9-10% OADC-0.05% Tween-80 broth containing 50 ⁇ g/mL hygromycin. The expression of recombinant M.
  • tuberculosis 30 kDa protein was verified by polyacrylamide gel electrophoresis and immunoblotting with polyvalent, highly specific rabbit anti-30 kDa protein immunoglobulins.
  • BCG Tice narG pMTB30 was found to produce approximately 10-20 times more 30 kDa antigen per mL of culture than a control BCG Tice strain.
  • the BCG Tice panCD genes were disrupted via allelic exchange.
  • the allelic exchange substrate was generated using a cloning strategy in which a panCD locus with a 1.3 kb deletion was created with an apramycin resistance (ap ) gene inserted at the site of the deletion.
  • This mutated allele was cloned into the allelic exchange vector phEX1 (a derivative of phAE87 [Bardarov S, Bardarov S Jr, Pavelka MS Jr, Sambandamurthy V, Larsen M, Tufariello J, Chan J, Hatfull G, Jacobs WR Jr. 2002.
  • BCG Tice was infected with this purified phage and then plated on 7H10 containing 50 ⁇ g/mL apramycin and 50 50 ⁇ g/mL calcium D-pantothenate to select for clones that had undergone a homologous recombination event.
  • Four apramycin resistant clones were obtained of which two were shown to be pantothenate auxotrophs. No growth was observed for the auxotrophs on plates or in broth without the addition of calcium D-pantothenate. In broth culture, the mutant strain grows at a rate similar to the wild-type strain in the presence of more than 10-50 ⁇ g/mL calcium D- pantothenate.
  • one of the pantothenate auxotrophic clones was plated at low density and a single colony was reisolated. Initial freezer stocks of the strain were prepared from this reisolated clone.
  • plasmid pMTB30 was engineered to express the M. tuberculosis Erdman 30 kDa major extracellular non-fusion protein from its own promoter (or any non-heat shock and non-stress protein gene promoter) by inserting a large genomic DNA restriction fragment containing the 30 kDa non-fusion protein gene plus extensive flanking DNA sequences into the plasmid's multi-cloning site using methods known to those skilled in the art of recombinant DNA technology.
  • the plasmid was first introduced into E. coli DH5 ⁇ to obtain large quantities of the recombinant plasmid.
  • the recombinant E. coli strain which was unable to express the M.
  • tuberculosis 30 kDa non-fusion protein was grown in the presence of 250 ⁇ g/ml hygromycin and the plasmid insert's DNA sequence was determined in its entirety.
  • the plasmid was introduced into M. smegmatis by electroporation using 6.25 kV/cm, 25 ⁇ F, and 1000 ⁇ as the conditions yielding the largest number of positive transformants.
  • the present inventors verified the presence of the recombinant plasmid by growth in the presence of 50 ⁇ g/ml hygromycin and the constitutive expression and export of recombinant 30 kDa non-fusion protein by polyacrylamide gel electrophoresis and immunoblotting with polyvalent, highly specific rabbit anti-30 kDa non-fusion protein immunoglobulins using methods known to those skilled in the art of recombinant DNA technology. Additionally, the inventors verified the correct expression and processing of the recombinant M. tuberculosis 30 kDa non-fusion protein, which was indistinguishable from its native counterpart by N- terminal amino acid sequencing.
  • the recombinant pSMT3 plasmid pMTB30 was subsequently introduced into M. bovis BCG Tice using 6.25 kV/cm, 25 ⁇ F, and 200 ⁇ as the optimal electroporation conditions.
  • Transformants were incubated in 7H9 medium supplemented with 2% glucose for 4 h at 37°C in an environmental shaker and subsequently plated on 7H11 agar with 20 ⁇ g/ml hygromycin. The concentration of hygromycin was gradually increased to 50 ⁇ g/ml as the transformants were subcultured to a new growth medium.
  • Recombinant BCG Tice cultures were maintained under the same conditions as the wild-type except that the 7H9 medium contained 50 ⁇ g/ml hygromycin.
  • tuberculosis 30 kDa major extracellular non-fusion protein by recombinant BCG Tice on SDS-PAGE gels and immunoblots.
  • the recombinant strain expressed much more of the M. tuberculosis 30 kDa major extracellular non-fusion protein than the wild-type both on Coomassie blue stained gels and immunoblots.
  • FIG. 1 b shows the expression of the M. tuberculosis 30 kDa major extracellular non-fusion protein by recombinant BCG Connaught on SDS-PAGE gels and immunoblots.
  • the recombinant strain expressed much more of the M. tuberculosis 30 kDa major extracellular non-fusion protein than the wild-type both on Coomassie blue stained gels and immunoblots.
  • Plasmid stability of recombinant strains of BCG was assessed biochemically. This biochemical analysis demonstrated that in the presence of hygromycin, broth cultures of the recombinant BCG strains maintain a steady level of recombinant non-fusion protein expression over a three month growth period. In the absence of hygromycin, the same cultures show only a slight decrease of non-fusion protein expression (on a per cell basis), indicating that the recombinant plasmid is stably maintained and only very gradually lost in bacteria growing without selective pressure (FIG. 1a and FIG. 1 b, lane 3). [0140] The stability of the various recombinant BCG strains of the present invention expressing M.
  • tuberculosis major extracellular proteins utilizing plasmid pNBVI and a promoter from the upstream region immediately adjacent to the glutamine synthetase gene glnA1 was examined.
  • Expression of the 30 kDa and/or 23.5 kDa proteins by rBCG30 Tice II, rBCG23.5 Tice I, and rBCG30/23.5 Tice I was stable for at least three months of continuous culture (approximately 30 generations) in medium that contained hygromycin for the positive selection of the plasmids.
  • culture of the strains for one month (approximately. 10 generations) in medium lacking hygromycin resulted in no decrease in expression levels.
  • pLC28 used to assay transmissibility of pGB9.2
  • pLC28 used to assay transmissibility of pGB9.2
  • pLC28 used to assay transmissibility of pGB9.2
  • pLC28 used to assay transmissibility of pGB9.2
  • pLC28 used to assay transmissibility of pGB9.2
  • pLC28 used to assay transmissibility of pGB9.2
  • R6K a genetic feature of E. coli S17
  • conjugative R6K derivative containing the mob region of plasmid RP4 and a mutant ori R6K which requires a functional ⁇ protein in trans for replication as provided by S17's ⁇ pir lysogen, was a gift from Olaf Schneewind, University of Chicago, Chicago, IL (Cheng et. Al. 1997)
  • R6K a naturally occurring, self-transmissible E. coli plasmid, was obtained from ATCC
  • pMTB30 pS
  • tuberculosis Erdman genomic DNA fragment containing the 30 kDa protein gene [fbpB; Rv1886c; (Cole ST, Brosch R, Parkhill J, Gamier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry III CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Barrell BG. et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
  • pNBVI another E. coli/mycobacteria shuttle plasmid conferring resistance to hygromycin and carrying the replication origin of plasmid pAL5000 was obtained from William Bishai [Johns Hopkins University, Baltimore, MD (Howard N, Gomez JE, Ko C and Bishai WR. 1995. Color selection with a hygromycin-resistance-based Escherichia co//-mycobacterial shuttle vector. Gene 166:181-2)]; and pVK173T (used to assay transmissibility of pGB9.2), an E.
  • coli/mycobacteria shuttle plasmid conferring resistance to ampicillin, apramycin, and hygromycin was a gift from Julian Davies, University of British Columbia, Vancouver, Canada (Paget E and Davies J. 1996. Apramycin resistance as a selective marker for gene transfer in mycobacteria. J Bacteriol 178:6357-60).
  • the shuttle plasmid pGB9 was modified in its E. coli portion by eliminating non-essential regions; the altered version of pGB9 was designated pGB9.2.
  • the original plasmid was digested with Bstv36l and SsfZ17l, the restriction sites were filled in and re-ligated, eliminating the can gene, a partial tef gene and part of the intergenic region of pACYC184 between the tef gene and the ori p15A. This step eliminated approximately 2.8 kb of DNA from pGB9 and left only the Tn5 derived kanamycin resistance gene as a selective marker.
  • the modified pGB9 plasmid pGB9.2 was assayed for its capacity to express recombinant proteins by inserting the M. tuberculosis 30 kDa protein gene (fbpBRv1886c; mycolic acid transferase) into the plasmid's multi-cloning site and driving expression of the protein by its endogenous promoter.
  • M. tuberculosis 30 kDa protein gene fbpBRv1886c; mycolic acid transferase
  • the plasmid pMTB30 (Horwitz et al., 2000) served as a template to generate a PCR product which encompassed the 30 kDa protein coding region preceded by approximately 500 bp of upstream DNA sequence (promoter region) and was flanked at the 5' end by Clal, Mlul, Ndel, Pad, and Hindlll restriction sites and at the 3' end by Pad, Ndel, Mlul, and BamHl restriction sites.
  • the 30 kDa protein gene cassette was lifted from the PCR product with Pad and inserted into the Pad site of pGB9.2 (FIG. 12). All constructs were first established in E. coli DH5 ⁇ and then electroporated into M.
  • the mycobacterial shuttle vector pNBV1 (Hyg r ) was modified by inserting a gene coding for apramycin resistance which allowed us to distinguish between strains carrying and pSMT3(Hyg r ).
  • the apramycin resistance gene [aac(3)-IVa], which encodes a type IV aminoglycoside 3-N-acetyl-transferase (261 aa), was inserted into pNBVI such that it replaced the short segment between the two Oral sites located in the region between the hyg r gene and the ColEI ori element; apramycin is mainly employed as an antibiotic in animal husbandry (Paget and Davies, 1996).
  • the mycobacterial shuttle vector pVK173T served as a template for the amplification product which encompassed the apramycin coding region preceded by approximately 200 bp of upstream (promoter) region and was flanked by Oral sites. Both insert orientations were obtained and verified by DNA sequencing across the insert junctions. Coomassie-stained gels of this two-plasmid system for the expression of M. tuberculosis 30 kDa protein in M. bovis BCG Tice are depicted in FIG. 11.
  • recombinant BCG strains prototrophs, auxotrophs and metabolically impaired strains
  • M. tuberculosis major extracellular non-fusion proteins can be prepared.
  • similar methodologies can be used to prepare recombinant BCG strains expressing M. leprae major extracellular non-fusion proteins including, but not limited to the M. leprae 30 kDa major extracellular non-fusion protein homolog of the M. tuberculosis 30 kDa major extracellular non-fusion protein (a.k.a. Antigen 85B), the M.
  • similar methodologies also can be used to prepare recombinant M. bovis BCG expressing the M. bovis 30 kDa major extracellular non-fusion protein homolog of the M. tuberculosis 30 kDa major extracellular non-fusion protein (a.k.a. Antigen 85B), the M. bovis 32A kDa major extracellular non-fusion protein homolog of the M. tuberculosis 32A kDa major extracellular protein (a.k.a. Antigen 85A), and other M. bovis major extracellular proteins.
  • the present invention is useful for preparing immunogenic compositions against a variety of intracellular pathogens, such compositions including, but not limited to BCG strains over expressing the major extracellular non-fusion proteins of M. tuberculosis, M. bovis or M. leprae.
  • Immunogenic compositions made in accordance with the teachings of the present invention are useful in eliciting immune responses in hosts.
  • the induced immune responses can be either humoral (antibody-based) or cellular and are useful in diagnostic, protective, or palliative applications.
  • the present invention provides recombinant attenuated intracellular pathogen immunogenic compositions such as rBCG that express their own endogenous extracellular proteins in addition to recombinant extracellular non-fusion proteins of closely related and/or other intracellular pathogens.
  • rBCG recombinant attenuated intracellular pathogen immunogenic compositions
  • BCG's endogenous extracellular proteins alone do not provide complete protection in all recipients.
  • present inventors have also demonstrated that merely co-injecting M. tuberculosis extracellular proteins along with traditional BCG does not result in immunogenic compositions superior to BCG alone.
  • the immunogenic composition includes a recombinant BCG immunogenic composition expressing only one immunogen, for example, but not limited to, the 23.5 kDa, 30 kDa, or 32 kDa major extracellular proteins of M. tuberculosis.
  • the recombinant BCG may express two or more immunogens, for example the 23.5 kDa and the 30 kDa major extracellular proteins of M. tuberculosis. This latter embodiment may be particularly effective as a immunogenic composition for preventing diseases in mammals.
  • the present inventors have proposed the non- limiting theory that the simultaneous over expression of the 23.5 kDa and the 30 kDa major extracellular proteins of M.
  • tuberculosis by a recombinant BCG may act synergistically to heighten the mammalian immune response against the intracellular pathogens of the present invention.
  • This theory is partially based on the observation that wild-type and recombinant BCG are deletion mutants of M. bovis that do not naturally express their own 23.5 kDa major extracellular protein.
  • the recombinant BCG of the present invention is transformed to express one or more recombinant major extracellular proteins simultaneously.
  • the polynucleotide sequences encoding the amino acid sequences of the recombinant major extracellular proteins may be on the same or different plasmids and may be expressed in the same or different amounts relative to each other.
  • immunogenic compositions utilizing BCG as the transformant can cause disseminated disease in immunocompromised persons such as those with AIDS. In rare cases the disseminated disease can be fatal. Therefore, in another embodiment of the present invention recombinant BCG strains, using BCG Tice as the wild-type parent, that are anticipated to be safe for use in eliciting an immune response in immunocompromised hosts have been developed. Four of these strains are auxotrophs and hence they multiply only in the presence of excess amounts of the amino acid for which they are auxotrophic. In one embodiment of the present invention, non-limiting exemplary examples include BCG tryptophan or glutamine. For this reason, their growth is regulatable by the host as will be discussed further below.
  • BCG strains suitable for use in immunosuppressed, or partially immunosuppresed mammals are not auxotrophs and hence not growth-regulatable.
  • These prototrophic BCG strains are allelic exchange mutants and are anticipated to be attenuated in immunocompromised hosts.
  • the present invention is not limited to auxotrophic strains of the transformant.
  • the present inventors anticipate that auxotrophs may not be suitable for all applications where the present immunogenic compositions are desirable.
  • auxotrophs are useful in regulating the transformant's growth in vivo, it requires that a second composition be administered timely and consistently to assure that the host develops the desired immune response. This requires vigilance on the part of the administering personnel, the host and the host's caregiver. Therefore, in order to minimize the requirement for a co-administered second composition, the present inventors have developed metabolically impaired immunogenic compositions that have a limited life span in the vaccine thus minimizing the possibility of disseminated disease.
  • the metabolically impaired immunogenic compositions are siderophore mutants that do not require the co-administration of an additional cofactor.
  • a siderophore auxotroph is "pre-loaded" with an essential mineral. Pre-loading as used herein refers to a process whereby the siderophore auxotroph is cultivated in a mineral rich environment in the presence of an exogenously supplied siderophore. Under these growth conditions the siderophore mutant acquires sufficient reserves of the essential mineral to permit several multiplications over several generations. Once the "pre-loaded" reserves of mineral are depleted, the siderophore auxotroph ceases dividing and is harmlessly cleared from the vaccine recipient.
  • the siderophore is a mycobactin or exochelin (or both) and the essential mineral is iron.
  • a BCG auxotroph was developed that is defective in pantothenate (vitamin B5).
  • the vaccinated host would take pantothenate supplements to allow the BCG to induce an immune response but if the BCG vaccine beings to disseminate and cause disease, the vaccinated host can stop taking the pantothenate supplement to stop the vaccine from multiplying.
  • the immunogenic compositions of the present invention can be used as both immunoprophylactic and immunotherapeutic compositions.
  • the composition of the immunoprophylactic embodiment of the present invention and the associated vaccination strategy will vary depending on the immune status of the host and the level of immune response desired.
  • Auxotrophic and metabolically impaired forms of the present invention are generally used when the vaccinee is immunocompromised and prototrophs are generally used in immunocompetent vaccinees.
  • vaccines including those made in accordance with the present invention, are administered to the immunologically na ⁇ ve vaccinee using a route of administration most appropriate for the vaccine type.
  • Routes of administration generally include oral, intradermal, intramuscular, subcutaneous, intranasal, intranodal or aerosolized and inhaled.
  • traditional vaccination protocols call for an initial immunization followed by one or more booster vaccines using the same immunogenic composition as initially administered.
  • a DNA prime-live vaccine boost strategy in mice can augment IFN- ⁇ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis.
  • Immunology 108:548-55 found that a prime-boost strategy involving a DNA prime followed by a live BCG boost did not increase protection against an M. bovis challenge.
  • Mollenkopf Mollenkopf H-J, Groine-Triebkom D, Andersen P, Hess J and Kaufmann S. 2001. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA.
  • Vaccine 19: 4028-35 did not find significantly improved protection against challenge with M. tuberculosis either by using a prime-boost strategy in which a recombinant Salmonella typhimurium vaccine carrier strain was administered first followed by a DNA vaccine or by using a prime-boost strategy in which the DNA vaccine was administered first followed by the Salmonella typhimurium vaccine carrier strain.
  • a prime-boost strategy in which a recombinant Salmonella typhimurium vaccine carrier strain was administered first followed by a DNA vaccine
  • the DNA vaccine was administered first followed by the Salmonella typhimurium vaccine carrier strain.
  • studies of BCG and DNA vaccines in immunotherapeutic models others have found that multiple vaccinations were not only ineffective but harmful, leading to an increase rather than a decrease in pulmonary pathology.
  • the present inventors have developed a novel prime-boost strategy for M. tuberculosis which includes first immunizing with a recombinant BCG over expressing a M. tuberculosis major extracellular protein and subsequently immunizing with the purified protein.
  • the administration of the vaccine in this way induces enhanced protection over that achieved by immunization with BCG alone, by immunization with rBCG30 alone, or even by immunization with BCG first followed later by immunization with the purified M. tuberculosis major extracellular protein.
  • the first immunization was with rBCG30, a recombinant BCG strain over expressing the M.
  • the immunogenic compositions useful in practicing the prime-boost strategy of the present invention include prototrophs, auxotrophs and metabolically impaired strains of rBCG.
  • the vaccination strategy of the present invention includes a vaccination strategy by which a live recombinant BCG vaccine over expressing a M. tuberculosis major extracellular protein, such as rBCG30, is administered first, and after a period of time, the purified M. tuberculosis major extracellular protein, such as r30, is administered one or more times.
  • the initial vaccination may be with any recombinant strain of BCG over expressing and secreting one or more M.
  • tuberculosis major extracellular proteins including but not limited to the 30 kDa major secretory protein (Antigen 85B), 32A major secretory protein (Antigen 85A), 32B major secretory protein (Antigen 85C), the 23.5 kDa major secretory protein (a.k.a. MPT64), the 16 kDa major secretory protein, the 23 kDa subunit mass superoxide dismutase, the 58 kDa subunit mass glutamine synthetase, the 71 kDa subunit mass heat shock protein, the 12 kDa subunit mass exported fragment of the 16 kDa alpha-crystallin protein, the 14 kDa secreted protein, etc.
  • Such extracellular proteins were previously shown to be immunoprotective against M. tuberculosis (Horwitz et al., 1995).
  • Each vaccine is administered intradermally or by another route, e.g. subcutaneously, percutaneously, intramuscularly, or even orally to a mammalian host.
  • the vaccine induces a cell-mediated immune response to the recombinant major extracellular protein.
  • the vaccine subsequently protects against infection with M. tuberculosis or other mycobacterial disease.
  • the present invention provides a comprehensive vaccination strategy and related immunogenic compositions suitable for treating, preventing and palliating intracellular pathogen diseases, specifically those associated with the genus Mycobacterium.
  • the present invention provides recombinant BCG strains that over express one or more major extracellular proteins of the genus Mycobacterium.
  • the rBCG of the present invention are transformed with one or a plurality of extrachromosomal plasmids that express one or more major extracellular proteins.
  • the rBCG (immunogenic compositions) of the present invention may be prototrophs, auxotrophs or metabolically impaired mutants.
  • the immunogenic compositions of the present invention may be used in immunocompetent and immunocompromised vaccinees and may be used alone or as part of a novel prime- boost strategy.
  • the following section details experiments that prove the safety and efficacy of the present invention.
  • the animal model selected (the guinea pig) by the present inventors is a well established experimental model that is considered predictive of results seen in other animals, including humans.
  • the immunogenic compositions of the present invention are tested for safety and efficacy using an animal model.
  • the studies utilize guinea pigs because the guinea pig model is especially relevant to human tuberculosis clinically, immunologically, and pathologically.
  • the guinea pig a) is susceptible to low doses of aerosolized M. tuberculosis; b) exhibits strong cutaneous DTH to tuberculin; and c) displays Langhans giant cells and caseation in pulmonary lesions.
  • M. tuberculosis b
  • c) displays Langhans giant cells and caseation in pulmonary lesions.
  • tuberculosis develop active disease over their lifetime (half early after exposure and half after a period of latency), infected guinea pigs always develop early active disease. While guinea pigs differ from humans in this respect, the consistency with which they develop active disease after infection with M. tuberculosis is an advantage in trials of immunogenic composition efficacy.
  • the following Examples serve to illustrate the novel aspect of the present invention.
  • Each example illustrates representative methods for testing safety and efficacy of the immunogenic compositions of the present invention and means of delivering the immunogens of the present invention using techniques closely related to, but different from the immunogenic composition of the present invention. Therefore, the following Examples serve to highlight the completely surprising and remarkable advance that the intracellular pathogen immunogenic compositions of the present invention represent to the field of infectious disease immunology. These Examples are for illustrative purposes only and are not to be deemed limiting.
  • Example 1 The immunization inocula made in accordance with the teachings of the present invention were prepared from aliquots removed from logarithmically growing wild-type or recombinant BCG cultures (the "bacteria”). Each aliquot of bacteria was pelleted by centrifugation at 3,500xg for 15 min and then washed with 1 x phosphate buffered saline (1 x PBS, 50 mM sodium phosphate pH 7, 150 mM sodium chloride). The immunization inoculums were then resuspended to a final concentration of 1x10 4 colony forming units (CFU) per mL in 1 x PBS and contained 1 ,000 viable bacteria per 100 ⁇ L.
  • CFU colony forming units
  • tuberculosis 30 kDa major extracellular non-fusion protein (r30), 100 ⁇ g in 100 ⁇ L Syntex adjuvant formulation (SAF), three times three weeks apart (time 0, 3, and 6 weeks); SAF consisted of Pluronic L121 , squalane, and Tween-80, and in the first immunization, alanyl muramyl dipeptide; and 4) SAF only (100 ⁇ L) (sham-immunized), three times three weeks apart (time 0, 3, and 6 weeks). An additional group of 3 animals was sham-immunized with SAF only (100 ⁇ L) and used as a skin test control. These and three to six other sham-immunized animals served as uninfected controls in the challenge experiments.
  • SAF Syntex adjuvant formulation
  • a large dose was used so as to induce measurable clinical illness in 100% of control animals within a relatively short time frame (10 weeks).
  • guinea pigs were individually housed in stainless steel cages contained within a laminar flow biohazard safety enclosure and allowed free access to standard laboratory chow and water.
  • the animals were observed for illness and weighed weekly for 10 weeks and then euthanized.
  • the right lung and spleen of each animal were removed and cultured for CFU of M. tuberculosis.
  • the rBCG30-immunized animals had 0.5 log fewer organisms in the lungs and nearly 1 log fewer organisms in the spleen than BCG-immunized animals.
  • LSD Tukey-Fisher least significant difference
  • CFU Colony Forming Units
  • tuberculosis 30 kDa major extracellular non-fusion protein nor does administration of the M. tuberculosis 30 kDa major extracellular non-fusion protein in microspheres that are of the same approximate size as BCG and like BCG slowly release the proteins over 60-90 days; nor does administration of the M. tuberculosis 30 kDa major extracellular non-fusion protein encapsulated in liposomes.
  • a very surprising aspect of this invention is that the rBCG30 strain induced protection superior to wild-type BCG even though the wild-type expresses and secretes an endogenous highly homologous 30 kDa major extracellular protein that differs from the M. tuberculosis protein by only two amino acids (see FIG. 1).
  • the improved protection of the recombinant strain is unlikely to be due to the small amino acid difference between the recombinant and endogenous proteins. More likely, it is due to the enhanced expression of the recombinant non-fusion protein compared with the endogenous protein. If so, then the abundant expression obtained by using a high copy number plasmid was likely an important factor in the success of the recombinant immunogenic composition.
  • Example 2 [0173] In this experiment, specific-pathogen free 250-300 g outbred male Hartley strain guinea pigs from Charles River Breeding Laboratories, in groups of 9, were immunized intradermally with 10 3 CFU of one of the following strains: Group A: BCG Tice Parental Control Group B: rBCG30 Tice I (pMTB30) Group C: rBCG30 Tice II (pNBV1-Pg/nA1-MTB30) Group D: rBCG23.5 Tice I (pNBVI -Pg/r?A1 -MTB23.5) Group E: rBCG30/23.5 Tice I (pNBVI -Pg/nA1 -MTB30/23.5) Group F: rBCG30 Tice II (pNBV1-Pg/t7A1-MTB30) and rBCG23.5 Tice I (pNBV1-Pg/nA1-MTB23.5) (5 x10 2 of each '
  • animals immunized with the recombinant BCG strain expressing r23.5 had marked erythema and induration in response to r23.5 that was significantly higher than in the BCG Tice or sham immunized animals.
  • animals immunized with the recombinant BCG strain expressing both r30 and r23.5 had marked erythema and induration in response to both of these proteins that was significantly higher than in the BCG Tice or sham immunized animals.
  • animals immunized with the new recombinant BCG strains (Groups C, D, E, and F), all of which express the recombinant proteins utilizing a promoter derived from the upstream region of the M. tuberculosis glnA1 gene, did not have greater erythema and induration to r30 than animals immunized with the rBCG30 Tice I strain, that expresses r30 utilizing a promoter derived from the upstream region of the M. tuberculosis gene encoding the 30 kDa major extracellular protein.
  • the airborne route of infection was used because this is the natural route of infection for pulmonary tuberculosis.
  • a large dose was used so as to induce measurable clinical illness in 100% of control animals within a relatively short time frame (10 weeks).
  • guinea pigs were individually housed in stainless steel cages contained within a laminar flow biohazard safety enclosure and allowed free access to standard laboratory chow and water.
  • the animals were observed for illness and weighed weekly for 10 wk and then euthanized.
  • the right lung and spleen of each animal was removed and cultured for CFU of M. tuberculosis on Middlebrook 7H11 agar for two weeks at 37°C, 5%CO 2 -95% air atmosphere.
  • Example 3 [0180] In this experiment, specific-pathogen free 250-300 g outbred male Hartley strain guinea pigs from Charles River Breeding Laboratories, in groups of 6, were immunized intradermally with 10 3 CFU of one of the following strains: Group I: BCG Tice Parental Control Group J: rBCG30 Tice I (pMTB30) Group K: rBCG30 Tice III (pNBV1-MTB30) Group L: rBCG23.5 Tice II (pNBV1-pMTB23.5) Group M: rBCG30/23.5 Tice IIA (pNBV1-MTB30/23.5tt) Group N: rBCG30/23.5 Tice I IB (pNBVI- MTB30/23.5t ⁇ ) Group O: rBCG32A Tice I (pNBVI -MTB32A). Group P: Sham immunized with buffer only (six animals).
  • Animals injected with a strain expressing r32A (Group O) and the 6 sham animals in Group P were skin- tested with 10 ⁇ g of purified recombinant M. tuberculosis 32A kDa major extracellular protein in 100 ⁇ L phosphate buffered saline. After 24 h, the diameter of erythema and induration was measured.
  • mice immunized with the parental BCG Tice strain (Group A) had no erythema and induration upon testing with r30, whereas animals (Groups J, K, M, N) immunized with strains expressing the recombinant 30 kDa protein had marked erythema and induration.
  • animals (Groups K, M, and N) immunized with strains expressing r30 in greater abundance than rBCG30 Tice I and utilizing a promoter derived from the upstream region of the 30 kDa protein gene had greater induration, a more reliable indicator of cutaneous delayed-type hypersensitivity than erythema, than animals immunized with rBCG30 Tice I.
  • Example 4 In this experiment designed to demonstrate protection from infection in immunized mammals specific-pathogen free 250-300 g outbred male Hartley strain guinea pigs from Charles River Breeding Laboratories, in groups of 18, were immunized intradermally with 10 3 CFU of one of the following strains: Group A: BCG Tice Parental Control Group B: rBCG30 Tice I (pMTB30) Group C: rBCG30 Tice III (pNBV1-MTB30) Group D: rBCG23.5 Tice II (pNBV1-pMTB23.5) Group E: rBCG30/23.5 Tice IIA (pNBV1-MTB30/23.5T ⁇ ) Group F: rBCG30/23.5 Tice MB (pNBVI- MTB30/23.5ti) Group G: rBCG32A Tice I (pNBVI -MTB32A) In addition, 12 animals were sham-immunized with antigen-free buffer as follows: Group H:
  • tuberculosis Prior to challenge, the challenge strain, M. tuberculosis Erdman strain (ATCC 35801), had been passaged through outbred guinea pigs to maintain virulence, cultured on 7H11 agar, subjected to gentle sonication to obtain a single cell suspension, and frozen at - 70°C).
  • This aerosol dose delivered approximately 20 live bacilli to the lungs of each animal.
  • the airborne route of infection was used because this is the natural route of infection for pulmonary tuberculosis.
  • a large dose was used so as to induce measurable clinical illness in 100% of control animals within a relatively short time frame (10 weeks).
  • guinea pigs were individually housed in stainless steel cages contained within a laminar flow biohazard safety enclosure and allowed free access to standard laboratory chow and water. The animals were observed for illness and weighed weekly for 10 wk and then euthanized. The right lung and spleen of each animal was removed and cultured for CFU of M. tuberculosis. The results are shown in Table 9 below.
  • Example 5 [0186] In this experiment designed to demonstrate the efficacy of the prime-boost strategy of the present invention, specific-pathogen free 250-300 g outbred male Hartley strain guinea pigs from Charles River Breeding Laboratories, in groups of 15, were immunized intradermally as follows: Group A: BCG Tice Parental Control (10 3 CFU) at Week 0 Group B: rBCG30 Tice I (pMTB30) (10 3 CFU) at Week 0 Group C: BCG Tice Parental Control (10 3 CFU) at Week 0 and 100 ⁇ g of r30 at Week 7 Group D: rBCG30 Tice I (pMTB30) (10 3 CFU) at Week 0 and 100 ⁇ g of r30 at Week 7 In addition, 11 animals were sham-immunized with buffer only as follows: Group E: Buffer only For tests of cutaneous delayed-type hypersensitivity (c-DTH) only, animals in groups of 6 were immunized as follows: Group F: BCG T
  • animals immunized with a recombinant BCG strain expressing r30 had marked erythema and induration in response to r30 that was significantly higher than in the BCG or sham-immunized animals.
  • animals immunized first with BCG or rBCG30, and then 7 weeks later with r30 had even greater erythema and induration.
  • the animals immunized with BCG plus r30 (Group H) had twice as much erythema and four times as much induration as animals immunized with only BCG.
  • mice immunized with rBCG30 + r30 had 0.25 log fewer CFU in the lungs and 0.13 log fewer CFU in the spleens than the animals immunized with only rBCG30.
  • the most efficacious vaccine was the combination of rBCG30 and r30. These animals had 0.4 log fewer CFU in the lungs and 0.28 log fewer CFU in the spleens than animals immunized with the combination of BCG and r30, the second most efficacious vaccine.
  • Table 12 CFU in Lungs and Spleens
  • Example 6 Specifically, Example 6 demonstrates that when the immunogens of the present invention are administered with, but not expressed in vivo by BCG, a high level of protective immunity is not achieved.
  • Immunization of guinea pigs with BCG plus recombinant M. tuberculosis 30 kDa major extracellular protein (r30) does not induce high level protection against challenge with M. tuberculosis.
  • Present inventors previously immunized guinea pigs with BCG plus r30 in a powerful adjuvant (SAF, Syntex Adjuvant Formulation). The r30 protein (100 ⁇ g per immunization) was administered intradermally three times.
  • SAF Syntex Adjuvant Formulation
  • C-DTH cutaneous delayed-type hypersensitivity
  • CFU Colony Forming Units
  • Example 7 demonstrates that the in vivo expression of the immunogens of the present invention using a Mycobacterium sp. closely related to BCG, but unable to replicate in mammalian hosts, fails to induce significant levels of protection against challenge with M. tuberculosis.
  • present inventors immunized guinea pigs with live recombinant M. smegmatis expressing the M. tuberculosis 30 kDa major extracellular protein (r30) in a form indistinguishable from the native form.
  • the expression and secretion of the M. tuberculosis 30 kDa major extracellular protein (r30) by M. smegmatis was equal to or greater than that of the recombinant BCG strain expressing and secreting the M. tuberculosis 30 kDa major extracellular protein.
  • the dose of recombinant M was equal to or greater than that of the recombinant BCG strain expressing and secreting the M. tuberculosis 30 kDa major extracellular protein.
  • Example 8 demonstrates that the slow release of the immunogens of the present invention by synthetic immunogenic composition microcarriers also fails to induce significant levels of protection against challenge with M. tuberculosis.
  • present inventors immunized guinea pigs with microspheres that are of the same approximate size as BCG and like BCG slowly release the M. tuberculosis 30 kDa major extracellular protein (r30) over 60 - 90 days.
  • One set of animals was immunized once with microspheres containing 10 mg of r30.
  • Another set of animals was immunized three times with microspheres containing 3.3 mg of r30. This amount was calculated to greatly exceed the amount of r30 protein expressed by the recombinant BCG strain.
  • CFU Colony Forming Units
  • Example 9 demonstrates that the slow release of the immunogens of the present invention by synthetic immunogenic composition microcarriers also fails to induce significant levels of protection against challenge with M. tuberculosis.
  • Example 10 Use of the Growth-Requlatable Auxotrophic Strains in Guinea Pigs [0203] To determine if iron-loaded rBCG-mbtB could persist in guinea pigs after immunization, nine male guinea pigs (Hartley strain, 250-300 grams) were given an intradermal inoculation of approximately 5 x 10 6 CFU of rBCG-mMB that had been iron-loaded by growing them in the presence of mycobactin J and iron.
  • Example 11 Use of the Growth-Regulatable Auxotrophic Strains in Humans [0204]
  • Example 11 provides a representative method for administering the auxotrophic embodiments of the present invention.
  • the growth-regulatable auxotrophic vaccines are used in humans as follows. Immunocompromised persons are immunized with the vaccines, for example the tryptophan auxotroph BCG strain. The person immediately begins supplementing his or her diet with tryptophan in sufficiently high amount so that the auxotroph multiplies at normal levels and induces a high level of protective immunity to tuberculosis. In most people, the multiplication of the recombinant BCG does not cause a health problem. The organism multiplies in the tissues to modest levels and is then cleared by the immune system. However, in some immunocompromised people, disseminated disease or other problems from bacterial multiplication develop. These people immediately stop the dietary supplement.
  • Example 12 Use of the Prototrophic Attenuated Strains [0207] Similarly, Example 6 details the use of prototrophic attenuated strains of the present invention.
  • BCG Mycobacterium bovis BCG Tice
  • rBCG30 a recombinant BCG Tice over expressing the M. tuberculosis 30 kDa major extracellular protein.
  • the challenge strain was Mycobacterium tuberculosis Erdman strain
  • each dose of 20 ⁇ g of r30 was first diluted to a final volume of 100 ⁇ L in phosphate buffered saline and then mixed with 150 ⁇ L of AS02A adjuvant (generously provided by GlaxoSmithKline Biologicals) or with no adjuvant.
  • AS02A adjuvant generously provided by GlaxoSmithKline Biologicals
  • guinea pigs were immunized in groups of 6 animals each.
  • DTH cutaneous delayed-type hypersensitivity
  • separate guinea pigs were immunized in groups of 15 animals each except for sham-immunized animals (9-15 per group) and BCG-immunized animals boosted with r30 without adjuvant in the third experiment (6 animals per group).
  • guinea pigs were individually housed in stainless steel cages contained within a laminar flow biohazard safety enclosure and allowed free access to standard laboratory food and water. The animals were observed for illness and weighed weekly for 10 weeks and then euthanized. The lungs, spleen, and liver of each animal were removed aseptically and inspected immediately for pathology, and the right lung and spleen were cultured for CFU of M. tuberculosis.
  • Sham-immunized animals had a very high burden of M. tuberculosis in their lungs and spleens (FIG. 14). Compared with sham-immunized animals, BCG- immunized animals had a markedly lower organ burden. Most importantly, in all three experiments, boosting BCG-immunized animals with r30 resulted in a substantial further reduction in the lung and spleen burden. Animals immunized with only rBCG30 had lower organ burdens of M. tuberculosis than animals immunized with only BCG. Remarkably, animals immunized with only rBCG30 also had fewer CFU in their organs than animals immunized with BCG and boosted.
  • Boosting animals immunized with rBCG30 had little impact on organ burden. In the lungs there was essentially no difference in CFU between boosted and non- boosted animals immunized with rBCG30. Whether animals were boosted with r30 in the presence or absence of adjuvant had no significant impact on organ burden in either BCG or rBCG30-immunized animals in Experiment 3, the only experiment in which this comparison was made.
  • the immunogenic compositions of the present invention represent an entirely new approach to the induction of immune responses against intracellular pathogens. Through a series of well designed experiments and thoughtful analysis, the present inventors have thoroughly demonstrated that protective immunity is only achieved when a precisely selected intracellular pathogen, or closely related species, is transformed to express recombinant extracellular proteins of the same or different intracellular pathogen in accordance with the teachings of the present invention.
  • the present invention can also be used to provide diagnostic, prophylactic and therapeutic benefits against multiple intracellular pathogens simultaneously. For example a recombinant attenuated intracellular immunogenic composition like M. bovis BCG can be designed to expressed immunoprotective immunogens against M. tuberculosis and Legionella sp. simultaneously.
  • Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J. Exp. Med. 183:1527-32. Harth G and Horwitz MA. 1999. Export of recombinant Mycobacterium tuberculosis superoxide dismutase is dependent upon both information in the protein and mycobacterial export machinery. A model for studying export of leaderless proteins by pathogenic mycobacteria. J. Biol. Chem. 274:4281-92. Harth G, Horwitz MA, Tabatadze D and Zamecnik PC. 2002.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions immunogènes comprenant des pathogènes intracellulaires atténués recombinants ayant été transformés de manière à exprimer des antigènes immunogènes recombinants de pathogènes intracellulaires identiques ou différents. Des compositions immunogènes exemplaires comprennent, mais sans caractère restrictif, des Mycobacteria recombinantes atténuées exprimant les protéines principales extracellulaires de non-fusion et/ou d'autres pathogènes intracellulaires. D'autres modes de réalisation concernent un pathogène intracellulaire atténué recombinant auxotrophe.
PCT/US2004/034206 2003-10-16 2004-10-15 Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci WO2005037222A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/595,385 US7622107B2 (en) 2003-10-16 2004-10-15 Recombinant intracellular pathogen immunogenic compositions and methods for use
EP04795381A EP1684798A4 (fr) 2003-10-16 2004-10-15 Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci
US12/296,660 US8163294B2 (en) 2003-10-16 2007-04-10 Growth regulatable recombinant BCG compositions
US12/296,666 US8287879B2 (en) 2003-10-16 2007-04-10 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US12/581,795 US8124068B2 (en) 2003-10-16 2009-10-19 Recombinant intracellular pathogen immunogenic compositions and methods of use
US12/986,598 US8383132B2 (en) 2003-10-16 2011-01-07 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51256503P 2003-10-16 2003-10-16
US60/512,565 2003-10-16

Related Child Applications (9)

Application Number Title Priority Date Filing Date
US10/595,385 A-371-Of-International US7622107B2 (en) 2003-10-16 2004-10-15 Recombinant intracellular pathogen immunogenic compositions and methods for use
US11/595,385 A-371-Of-International US20070123602A1 (en) 2005-11-29 2006-11-09 Use of thermal reversible associations for enhanced polymer interactions
US12/296,666 Continuation-In-Part US8287879B2 (en) 2003-10-16 2007-04-10 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US12/296,666 Continuation US8287879B2 (en) 2003-10-16 2007-04-10 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
USPCT/US0207/066350 Continuation-In-Part 2007-04-10
US12/296,660 Continuation-In-Part US8163294B2 (en) 2003-10-16 2007-04-10 Growth regulatable recombinant BCG compositions
PCT/US2007/066350 Continuation-In-Part WO2007121194A1 (fr) 2003-10-16 2007-04-10 Compositions immunogènes à agents pathogènes intracellulaires recombinés immunostimulants, et procédés d'utilisation
US12296666 Continuation-In-Part 2008-10-09
US12/581,795 Division US8124068B2 (en) 2003-10-16 2009-10-19 Recombinant intracellular pathogen immunogenic compositions and methods of use

Publications (2)

Publication Number Publication Date
WO2005037222A2 true WO2005037222A2 (fr) 2005-04-28
WO2005037222A3 WO2005037222A3 (fr) 2005-09-09

Family

ID=34465361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034206 WO2005037222A2 (fr) 2003-10-16 2004-10-15 Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci

Country Status (4)

Country Link
US (2) US7622107B2 (fr)
EP (2) EP2206514B1 (fr)
DK (1) DK2206514T3 (fr)
WO (1) WO2005037222A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121193A1 (fr) * 2006-04-10 2007-10-25 The Regents Of The University Of California Compositions immunogènes à agents pathogènes intracellulaires recombinés à croissance régulable, et procédés d'utilisation
US20120156169A1 (en) * 2006-07-25 2012-06-21 Institut Pasteur Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy
US8287879B2 (en) 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8383132B2 (en) 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037222A2 (fr) * 2003-10-16 2005-04-28 The Regents Of The University Of California Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci
US8932846B2 (en) * 2007-06-14 2015-01-13 The Regents Of The University Of California Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
WO2016157200A1 (fr) * 2015-04-03 2016-10-06 Foschneano Gido Moyen et procédé de torréfaction salée de produits alimentaires
WO2018026729A1 (fr) 2016-08-01 2018-02-08 The Regents Of The University Of California Vaccin à plate-forme unique sûr et efficace contre des agents sélectionnés de niveau 1 et d'autres agents pathogènes
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN113999865B (zh) * 2021-10-09 2023-06-16 安徽理工大学 结核分枝杆菌融合蛋白ar2及其构建与表达纯化方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
EP0347425B1 (fr) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Vaccin mycobacterien recombinant
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
US5736367A (en) * 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US6599510B1 (en) 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5679515A (en) * 1994-10-03 1997-10-21 Pathogenesis Corporation Mycobacterial reporter strains and uses thereof
US5700683A (en) * 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
EP1005365B1 (fr) * 1997-01-21 2008-01-02 The Regents Of The University Of California Epitopes d'un antigene extracellulaire
US6471967B1 (en) * 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
DE10026752A1 (de) 2000-05-30 2001-12-06 Kloeckner Humboldt Wedag Gleitschuhlagerung für Drehtrommeln wie z.B. Rohrmühlen
EP1164488A1 (fr) 2000-06-14 2001-12-19 Canal+ Technologies Société Anonyme Mise au point à distance dans un environement de système incorporé
GB0014845D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Vaccine
WO2002004018A2 (fr) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Vaccin de mi-vie et procédé pour renforcer l'immunité anti-mycobactérienne
US7722861B2 (en) * 2002-02-19 2010-05-25 Svetoslav Bardarov, legal representative Attenuated Mycobacterium tuberculosis vaccines
WO2005037222A2 (fr) * 2003-10-16 2005-04-28 The Regents Of The University Of California Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1684798A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163294B2 (en) 2003-10-16 2012-04-24 The Regents Of The University Of California Growth regulatable recombinant BCG compositions
US8287879B2 (en) 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8383132B2 (en) 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
WO2007121193A1 (fr) * 2006-04-10 2007-10-25 The Regents Of The University Of California Compositions immunogènes à agents pathogènes intracellulaires recombinés à croissance régulable, et procédés d'utilisation
US20120156169A1 (en) * 2006-07-25 2012-06-21 Institut Pasteur Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Also Published As

Publication number Publication date
DK2206514T3 (da) 2014-04-22
US7622107B2 (en) 2009-11-24
EP2206514A2 (fr) 2010-07-14
US20100092518A1 (en) 2010-04-15
EP1684798A4 (fr) 2007-12-05
WO2005037222A3 (fr) 2005-09-09
US20070128216A1 (en) 2007-06-07
EP2206514A3 (fr) 2010-12-08
US8124068B2 (en) 2012-02-28
EP2206514B1 (fr) 2014-01-08
EP1684798A2 (fr) 2006-08-02

Similar Documents

Publication Publication Date Title
US8124068B2 (en) Recombinant intracellular pathogen immunogenic compositions and methods of use
US10010595B2 (en) Live recombinant booster vaccine against tuberculosis
JP2008521449A (ja) エンドソームエスケープ能力増強組み換えｂｃｇ株類
US9931391B2 (en) Prevention and treatment of mycobacterium infection
ZA200502596B (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
Badell et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells
US8932846B2 (en) Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
JP2006501304A5 (fr)
Hernandez-Pando et al. Recombinant BCG vaccine candidates
US8163294B2 (en) Growth regulatable recombinant BCG compositions
US10406219B2 (en) Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same
US8383132B2 (en) Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US20030124135A1 (en) Recombinant intracellular pathogen vaccines and methods for use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007128216

Country of ref document: US

Ref document number: 10595385

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004795381

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004795381

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10595385

Country of ref document: US